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ABSTRACT

Characterization of Anti-Pichinde Virus Monoclonal
Antibodies for the Directed Delivery of
Antiviral Drugs and Toxins

by

Noah Jefferson Burns, III, Doctor of Philosophy
Utah State University, 1989
Major Professor: Dr. Robert W. Sidwell
Dissertation Advisor: Dr. Bill B. Barnett
Department: Biology
Mouse monoclonal antibodies directed against Pichinde virus (PCV)
were produced to evaluate their application as vehicles for the delivery of
antiviral drugs or toxins to virus-infected cells. Four monoclonal
antibodies, PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D3, were of the IgG2a
subisotype and reacted with acetone-fixed and live PCV-infected Vero-76
cells.

In vivo stained splenic macrophages derived from PCV-infected

hamsters that had been injected with fluorescein-labeled PC4.9A6 (FITC9A6) demonstrated a 400% increase in total fluorescence over similarly
treated, non-infected cells when analyzed by flow cytometry.

This is an

indication that FITC-9A6 does have some ability to specifically target PCVinfected cells in vivo. Radioimmunoprecipitation of viral proteins showed
that all the antibodies precipitated two different PCV proteins, one of 64,000
daltons and another of 38,000 daltons. These proteins are, respectively, PCV
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nucleoprotein (NP) and a breakdown product of NP that is present in PCVinfected cells.
An immunofluorescent assay (IFA) for PCV was developed. This IFA
was used for antiviral drug assays against PCV. The assay was performed by
adding fluorescein-labeled anti-PCV monoclonal antibody to fixed, virusinfected cells at 24 h after infection and counting the fluorescent cells. The
50% effective dose (EDso) for ribavirin against PCV using this IFA was 6.0
IJ.g/ml.

The EDso of ribavirin using inhibition of marginal PCV

cytopathogenic effect after 12 days was 6.0 IJ.g/ml and using plaque reduction
after 5 days is 2.5 IJ.g/ml, indicating that this IFA was of comparable
sensitivity.
An immunotoxin (IT) was produced by the conjugation of gelonin to
PC4.9A6. This IT was tested in vivo in PCV-infected MHA hamsters. It was
not active against the disease at the dosage tested and by the intraperitoneal
(i.p.) treatment route employed in this study.

The positive control, rib-

avirin, administered i.p. for 14 days at a dosage of 40 mg / ml significantly
increased the number of survivors.

Three of 5 IT toxicity control animals

developed some humoral response that inhibited PC4.9A6 binding to infected cells. They did not show any humoral response to the gelonin moiety
of the IT.
(115 pages)

CHAPTER I
INTRODUCTION

The Arenaviridae family contains a group of viruses that have proven
to be serious human health threats.

Some members of this family of

viruses, Junin, Machupo, and Lassa (the etiological agents of Argentine
hemorrhagic fever, Bolivian hemorrhagic fever, and Lassa fever ,
respectively), are endemic in some areas of Africa and South America.
Mortality rates vary from 3 to 30% of infected individuals during outbreaks
of these viral diseases (L \.
Currently available therapies, such as treatment of patients with
immune plasma from previously infected individuals, have not effectively
controlled outbreaks of any of the above-mentioned viral diseases.
Treatment of these diseases with ribavirin, the antiviral drug that is
currently the most effective drug against Lassa fever, does not ensure 100%
survival of the infected individuals (2). Also, it is very difficult to ensure an
adequate supply of im:-_mne plasma in many of the areas where the
outbreaks may occur because of the remoten ess of the locations and
inadequate public health facilities available.

Because these diseases are

carried by rodents, it is difficult to determine where the next outbreak might
occur. There are few effective preventative measures to protect against these
diseases because of continuing difficulties in developing suitable vaccines
against the hemorrhagic fever viruses.

Thus, the arenaviruses do represent

a severe health threat in countries where these viruses are endemic.
Pichinde virus (PCV) is an arenavirus from South America that is much
less pathogenic to humans but still causes a very severe hemorrhagic disease
in guinea pigs (1) and hamsters (3).

Because of the potential for human
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disease associated with the more virulent arenaviruses, PCV is a good in
vivo model for the study of the pathogenesis of hemorrhagic diseases as well
as for the evaluation of the efficacy of novel antiviral therapies to combat the
illnesses.
Because of the dependence of viruses on cellular enzymes and ribosomes
for protein synthesis and replication, it is very difficult to target a therapeutic
agent to inhibit only virus-specific biochemical events.

Compounds that

interfere directly with the replication of the viral genome or with the
synthesis of viral proteins will often inhibit similar events in the
noninfected host cell.

Thus, new means of targeting a· •tiv1ral drugs

specifically to infected host cells have the potential to significantly increase
the therapeutic index of an antiviral compound. Theoretically, the targeting
of antiviral agents to infected cells should bring about a significant decrease
in overall host toxicity and an accompanying increase in the specificity of
action of the antiviral agent.
In this research project, the effectiveness of a new means of targeting
antiviral drugs or toxins using monoclonal antibodies

dire :~ ed

against

Pichinde virus (PCV) proteins was studied. Monoclonal antibodies produced
against PCV were characterized as to their isotype and subisotype, reactivity
with PCV-infected cells in vitro and in vivo, and reactivity with PCV-specific
proteins. Also, because of the anticipated low yields of immunoconjugate
production and the insufficient development of PCV cytopathogenic effect
(CPE) in cell culture, an antiviral assay that used a minimum of compound
but that still had a readily determined endpoint was developed.

A

promising anti-PCV monoclonal antibody was conjugated with the plant
toxin gelonin. The resulting immunotoxin was tested in vivo to determine
its antiviral effectiveness in preventing the development of hemorrhagic

3

disease in MHA hamsters infected with lethal doses of PCV. The humoral
responses of the hamsters to the monoclonal antibody and the toxin
components of the immunotoxin were also studied.
This study provided a basis for the evaluation of the use of
immunotoxin conjugates for the treatment of arenaviral hemorrhagic
disease.

Insights were gained into the development of more adequate

screening procedures for the determination of the suitability of individual
monoclonal antibodies for use as vehicles for the targeted delivery of
antiviral drugs and toxins. This study provided an opportunity to test the
pre dictive nature of the surface binding and viral p eptid1· binding
characteristics of monoclonal antibodies in determining the adequacy of
screening procedures used to select monoclonal antibodies for use in this
drug/toxin delivery system.
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CHAPTER II
REVIEW OF THE LITERATURE

PICHINDE VIRUS

Initial isolation and characterization of Pichinde virus. Pichinde virus
was first reported as a new member of the Tacaribe group of viruses by
Trapido and Sanmartin in 1970 (64).

It was isolated from a chronically

infected South American rodent, Oryzomys albigularis, found in the
Pichinde v Hey of Columbia, hence the name Pichinde virus.

Pichinde

virus was recovered from the brain, heart, lung, liver, spleen, kidney,
adrenal gland, serum, and urine of naturally infected animals.

It was

included in the Tacaribe group of viruses because of its reactivity in
complement fixation (CF) tests with Tacaribe-group immune fluids .

Its

distinctiveness was also established on the basis of CF and plaque
neutralization tests using Pichinde immune ascites fluids, normal serum,
and homolog: us serum (43).
In 1971, the lymphocytic choriomeningitis virus (LCM)-like viruses were
all classified in the group arenaviruses (53).
discovered Pichinde virus (43) .

This included the newly

The group was named from the Latin

arenosus, or sandy, on the basis of the grainy appearance of the interior of

the virion when viewed by ultra-thin section (45). The graininess is due to
the incorporation of host cell ribosomes into the arenavirus virion. This is a
feature that appears to be specific for arenaviruses. The virus group is now
the family Arenaviridae.
Mifune et al. (43) characterized the virus as to its size, thermal stability,
pH stability, density in sucrose, ether lability, and sensitivity to nucleic acid

•
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inhibitors such as 5-iodo-2'-deoxyuridine (IdU),

1-~-D-arabinofurano

sylcytosine (ara-C), actinomycin D, and 6-azauridine. Their results indicated
that Pichinde virus was indeed similar to LCM in its physical properties,
demonstrating a size of 50-100 Jlm, relative heat stability, stability over a pH
range of 6.0 to 9.0, a buoyant density of 1.18 gfcm3, and an ether-soluble lipid
envelope. Moreover, it was inhibited by actinomycin D and 6-azauridine,
known RNA polymerase inhibitors, at concentrations that did not affect the
replication of DNA viruses. It was also resistant to inhibition by known
DNA antagonists IdU and ara-C. Arenaviruses have also been shown to be
inhibited by the known antiviral agent ribavirin {:-2).
Since the primary isolation of Pichinde virus by Trapido and Sanmartin
(64) and the initial characterization of the virus by Mifune et a!. (43), much
work has been done in describing both its genetic and antigenic structure.
Pichinde virus has been shown to contain several species of RNA. The
Pichinde virion contains large (L) and small (S) segments of RNA that have
been shown to be the genomic material of the virus (50, 70). The virion also
contains host cell ribosomal RNAs of 28 S, 18 S, and :-6 S (13). Size estimates
for the L RNA segment range from 2.63 x 106 to 2.83 x 106 daltons and for the
S RNA segment from 1.26 x 106 to 1.31 x 106 daltons, as determined by
Ramsingh et a!. (50).
Historically, the arenaviruses have been classified as either Old World
(e.g., LCM and Lassa viruses) or New World (e.g., Pichinde, Machupo, and
Tacaribe viruses) depending upon where, geographically, the virus isolates
were obtained. Because LCM has been isolated in both the Old and New
World, a second classification based on serological reactivity was developed.
This classification divides the Arenaviridae into two complexes: i) the LCM
complex containing Ippy, LCM, Lassa, Mabala, and Mopeia viruses and ii) the
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Tacaribe complex containing Amapari, Flexal, Junin, Latino, Machupo,
Parana, Pichinde, Tacaribe, and Tamiami viruses. The latter classification is
based on serological cross-reactivity of the members with both polyclonal
and monoclonal antibody preparations. Cross-reactive epitopes within each
complex and also between the two complexes have been demonstrated (71).
Direct analysis of sequence data from the genomic regions that code for the
nucleoprotein (NP) and the glycoprotein precursor protein (GPC) confirm
that Pichinde, Lassa, and LCM are indeed all closely related (7, 58, 68).
Synthesis of both the NP (molecular mass [m.m.] = 64,000-66,000 daltons)
and GPC (m.m.

=

-80,000 daltons) has been mapped to the S segment of the

Pichinde virus genome (4, 26) .

Sequence analysis, combined with

appropriate S RNA segment DNA probes, has shown that Pichinde-virusinfected cells contain full length viral and viral-complementary S RNAs.
Two distinct subgenomic S RNAs were also detected in infected cells. The
subgenomic viral-complementary mRNA coded for NP and the subgenomic
virus-sense mRNA codes for the GPC. These observations have resulted in
the proposal of an ambisense coding strategy to explain how these proteins
are synthesized from the same viral RNA (4, 7).

This ambisense strategy

d enotes only that both the viral-sense and the viral-complementary mRNA
transcripts can be used to synthesize viral gene products from the viral
genomic S RNA.
Pichinde virus has been shown to code for three major proteins. The NP
makes up an estimated 70% of the entire protein mass of the virus. The
cleavage products of GPC, GP1, and GP2 make up a total of about 25 % of the
viral protein mass . There are approximately 400 molecul es of each
glycoprotein on the surface of the virion and approximately 1500 molecules
of NP on the inside of the virion (9, 69).
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The m .m.s of the different viral glycoprotein species are disputed in the
literature (6, 9, 27, 69). Vezza et a!. (69) reported the m.m. for NP to be 66,000
daltons and the m.m: for GP1 and GP2 to be 64,000 and 38,000 daltons,
respectively. Harnish et a!. (27) reported the m.m. for NP to be 64,000 daltons
and the m .m. for GP1 and GP2 to be 52,000 daltons and 36,000 daltons,
respectively. The difference in the m.m. of GP1 between the two groups is
difficult to explain. Both experiments were done in a baby hamster kidney
cell line (BHK-21), suggesting that simple differences in the availability of
cellular glycosylases will not suffice as the explanation for the observed
difference.
Other minor proteins have been reported for Pichinde virus.

This

includes a protein, coded on the L segment of the genome, that is thought to
be the viral RNA polymerase. It has a m.m. of 200,000 daltons. There are
also several other minor proteins, ranging from 12,000 to 77,000 daltons,
whose functions have not yet been identified (9).
Animal models of Pichinde virus-mediated hemorrhagic disease. Since
the initial isolation of Pichinde virus in 1971, it has become the prototype
virus for studying the in vivo pathogenesis of arenaviral hemorrhagic
disease in small animals such as the Syrian hamster strain MHA (21, 44) and
the guinea pig strain 13 (32).

Pichinde virus is preferred because of its

extremely low potential for infectivity and disease in humans and also
because of the reproducibility of the viral infection in these small animals.
In addition, because it has been adapted to cause a lethal disease in guinea
pigs, it is considered to be an alternative model to Lassa fever in these
animals.

Lassa fever virus does not produce clinical disease in MHA

hamsters (32).
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Pathogenesis of viral hemorrhagic fevers. The comparative study of the
pathogenesis of Pichinde virus in two different hamster strains reported by
Murphy et a!. (44) showed that only the MHA strain of adult hamsters was
susceptible to lethal infection. The LVG strain of Syrian hamsters, though
showing some signs of disease early in the infection, was able to clear the
virus completely from its system by day 10 post-infection.
Infection of MHA hamsters with Pichinde virus resulted in a severe
hemorrhagic disease in the animals, grossly characterized by edema around
the eyes, bleeding from the eyes and nose, and diarrhea, as well as a lethargy
as the disease progressed. Intern >lly, infection of the macrophages in the
spleen resulted in the depopulation of the organ with destruction of both the
red pulp and the white pulp regions.

In moribund animals, antigenic and

necrotic tissue was observed to be held in place by only an intact splenic
capsule.
In the liver, the Kuppfer cells and hepatocytes were the targets of viral
infection. Necrotic Kuppfer cells and hepatocytes were present as foci in
infected livers by day 10. A large am: :mt of cellular debris was present in the
sinusoids of the organ. The lesions observed in the infected livers have been
reported to be very similar to the lesions caused by Lassa fever virus in
humans (44, 72).
An observation of interest regarding the natural resistance of the LVG
hamsters to Pichinde virus infection is that this resistance can be abrogated
by immunosuppression with cyclohexamide. Also, immunosuppression of
the MHA hamsters with cyclohexamide did not prevent lethal infection
with the virus.

Kenyan et a!. (35) reported that immunosuppression of

guinea pigs that were later infected with virulent Junin virus resulted in no
apparent effect on the development of the disease in these animals. They
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also demonstrated that immunosuppressed animals infected with an attenuated strain of Junin developed fatal Argentine hemorrhagic fever, whereas
the immunocompetent, infected animals did not.

Immunosuppression

prevented the development of antibody-dependent virus-specific cytotoxic
spleen cell activity.

Also, no harmful effects induced by the immune

response were observed in any of the infected, immunocompetent animals.
This evidence suggests that, unlike the immune complex-mediated disease
observed in LCM-infected animals (10), there is a direct role for the
arenaviruses of the Tacaribe complex and Lassa fever virus in the
pathogenesis of the hemorrhagic fevers (44).
The specific mechanisms of viral pathogenesis due to arenaviral
infection have been difficult to elucidate. Liu (40) has described the effect of
PCV on the hearts of infected guinea pigs. The beating hearts, observed in
situ on days 11 to 19 post-infection, showed three types of cardiac
abnormalities: i) engorgement of the superior and inferior vena cavae with
an accompanying dilation of the right side of the heart, ii) sluggish cardiac
contractions and diminished heart rate, and iii) a systolic bulge at th:. apex of
the right ventricle. Cardiac and other tissues sampled immediately after the
death of the animals did not manifest any obvious histopathological lesions.
Jahrling et a!. (32) have previously reported that no virus was recovered
from the hearts of infected guinea pigs. Thus, there appears to be no direct
histopathological evidence for an involvement of Pichinde virus in causing
cardiac dysfunction.
An earlier study by Liu et a!. does shed some light on how Pichinde
virus infection may be indirectly involved in producing the observed cardiac
dysfunction (41).

Infection of guinea pigs with Pichinde virus caused an

increase in the serum levels of the leukotriene LTD4. Leukotrienes are
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eicosanoids and are related to the prostaglandins. They are synthesized from
arachidonic acid and have been shown to act as vasoconstrictors and to also
increase vascular permeability.

The leukotrienes LTC4 and LTD4 are

thought to be the most important components of Slow Releasing Substance
of Anaphylaxis (SRS-A), which causes smooth muscle contraction often seen
in allergic asthma. Treatment of infected animals with the LTD4 antagonist
FPL-55712 led to an increase in mean survival time and food intake as well
as a decrease in weight loss. Treatment did not mitigate a persistent fever in
the guinea pigs . These studies propose that infection with Pichinde virus
induced the overproduction of these leukotrienes and, indirectly, that these
biochemical "lesions" disturbed the chemical homeostasis of the heart
muscle, eventually leading to the death of the animal.

MONOCLONAL ANTIBODIES

Monoclonal antibody technology. With the introduction of monoclonal
antibody technology by Kohler and Milstein in 1975 (37), the scientific
research community was provided a very powerful tool for probing,
potentially, the molecular secrets of any immunogen. This technology has
proven itself far superior over conventional polyvalent sera in that:

i)

antibody of a single specificity can be obtained; ii) hybridomas secrete an
almost unlimited amount of the desired antibody; iii) impure or partially
purified antigen can be used to produce monospecific antibody; iv) many
different specificities can be isolated from a single mouse; v) specific B cells
are enriched during hybridization; vi) low-producing B cells, when fused to
myeloma cells, become much higher producers; vii) the hybridoma can be
genetically manipulated to produce non-naturally occurring antibody; and
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viii) the technique of fusing immortalized cells to normal cells will bestow
the immortalized phenotype to a variety of cells such as T cell clones (3, 36).
In 1975, Kohler and Milstein (37) published a paper in which they
described a technique for fusing antibody-producing B cells with
immortalized myeloma cells. This technique created a hybridoma that was
immortalized and that retained the antibody-secreting phenotype of the B
cell fusion partner. It was quickly recognized that this approach to producing
antibody of a single, defined specificity would revolutionize nearly all fields
in biology, biochemistry, and molecular biology. The advent of monoclonal
ar :ibody technology has not only led to great strides in researching antigenantibody interactions, but it has had tremendous impact on such diverse
fields as the diagnosis and treatment of disease (5, 51); purification of
proteins and other biomolecules; the development of new, safer vaccines (1,
34, 60); and the development of customized enzymes (48, 62, 63).

This

technology has also revolutionized the field of immunology, allowing the
elucidation of the biosynthesis of immunoglobulins, immunoglobulin class
swiL~ing,

and the characterization of many of the subgroups of the T cell

family of immune cells. These subsets of T cells have now been shown to
have specific, critical roles in the development of both humoral and cellular
immunity.
The production of monoclonal antibodies is accomplished as described
below.

Spleen cells are taken from a donor that has been previously

immunized with the antigen of interest. These cells are teased from the
splenic capsule and collected.

Myeloma cells that are deficient in

hypoxanthine or adenosine phosphoribosyl transferase (HPRT or APRT) are
then mixed with the immune spleen cells, and the cells are then fused
together via an agent such as polyethylene glycol. The fused cells are then
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gently suspended in growth media and plated out. The plates are then fed
with media containing hypoxanthine or adenosine, aminopterin, and
thymidine. This is done in order to select only cells that have been fused
together successfully. The selection is based upon the deficiencies in the
purine nucleotide salvage pathways of the myeloma cells and the inhibition
of de novo purine nucleotide biosynthesis by aminopterin.

Only

hybridomas that contain a functional salvage pathway, HPRT- or APRTcontaining cells, are capable of growing in the selection media. Theoretically,
only the hybridomas that meet these requirements can grow, because of the
presence of the salvage pathway enzym cs HPRT and APRT from the
immune B cell fusion partner. Unfused B cells and myelomas die after a few
days of exposure to the selection media (22).
There are problems associated with the production of monoclonal
antibodies. Because hybridomas contain 2-10 times the normal complement
of genetic material, they often throw out the extra chromosomal baggage.
This can result in a change in the phenotype of the cell. Occasionally, the
antibody secretory genes are deleted from a.n unstable hybridoma and
monoclonal antibody production is lost. Other times, the salvage pathway
genes are lost and the hybridoma dies. Hybridomas that survive selection
and that are positive antibody producers are cloned by limiting dilution to
isolate clones derived from individual hybridomas and retested for antibody
production. It is not unusual for a hybridoma to be recloned and rescreened
three or four times prior to using it for producing large quantities of
antibody.
Therapeutic conjugates employing monoclonal antibodies for directed
drug or toxin delivery. The concept of using antibodies for the delivery of
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drugs to infected or malignant tissues can be traced back to Paul Ehrlich who
postulated the "magic bullet" idea during the late nineteenth century (30) .
With the advent of monoclonal antibody technology in 1975 (37), it became
possible to develop antibodies that react specifically with tumor-associated
antigens. Monoclonal antibodies were made against a variety of different
tumor cell antigens and were then used experimentally as therapeutic agents
with the hope of exploiting the exquisite specificity of these molecules in
destroying malignant tissues (28). It soon became evident that, even though
monoclonal antibodies were directed against tumor-specific antigens, they
were much better suited for use as diagnostic reagents, rather than

~s

therapeutic agents for the treatment of cancer.
As clinicians were seeking to develop monoclonal antibodies for use as
therapeutic agents, they were also developing new chemotherapeutic agents
to specifically inhibit and kill cancer cells. These agents were designed to
inhibit specific biochemical reactions, such as the methylation of DNA by
dihydrofolate reductase, that occur at much higher than normal levels in
rapidly replicating tumor cells.

Many of the newly developec

chemotherapeutic agents were promising against tumor cells in vitro, but
later proved to be too toxic when tested in vivo. Host toxicity is still the
single most significant problem associated with cancer chemotherapeutic
agents.
As th ese events took place, other scientists were purifying and
characterizing potent toxins derived from both bacteria and plants. The
earliest plant toxins to be purified and characterized were ricin and abrin.
These were isolated from Ricinus communis (Castor bean) and Abrus
precatorius (Jequirity bean), respectively (24, 19).

At the end of the

nineteenth century, Paul Ehrlich was able to demonstrate the separate
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immunological identities of these two toxins by demonstrating that mice
immunized with either toxin were not protected against lethal challenge
with the other (19). Several other plant and bacterial toxins, such as gelonin
(59), pokeweed antiviral protein, modeccin, diphtheria toxin, and

Pseudomonas exotoxin A ·(14), have since been isolated and characterized for
use in the construction of therapeutic immunoconjugates for use in cancer
and antiviral immunotoxin therapy (2, 8).
Plant and bacterial toxins are composed of either a single A chain protein
monomer or a heterodimer composed of an A and a B chain. The A chain of
a heterodimeric toxin contains the catalytic (toxin) domain, whereas the B
chain usually contains a lectin or lectin-like molecule that mediates binding
of the entire toxin molecule to sugar residues expressed on the surface of
cells. The B chain domain also may be important in the translocation of the
toxin across the cell membrane (2).
The catalytic domains of A chains of either the monomeric or
heterodimeric toxins require entry into the intact cell before toxic effects are
observed. Once inside the cell, the toxins exert their effects on the eukaryotic
28 S ribosomal RNA. Endo et a!. (16) have demonstrated that ricin, abrin,
ricin A chain, and modeccin inactivate the 28 S ribosomal subunit by
modifying both or either the guanosine4323 or adenosine4324 nucleoside
residues. This effectively shuts down the protein synthesis machinery of the
cell, resulting in cell death.
Because of the dissatisfying results obtained in using monoclonal
antibodies as therapeutic agents for cancer, oncologists soon realized that
what monoclonal antibodies lacked was the "punch" associated with the
often too-toxic chemotherapeutic agents (24) .

They theorized that by

combining the specificity of monoclonal antibodies with the potency of
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chemotherapeutic agents or the newly discovered toxins, the "magic bullets"
originally put forth by Ehrlich, could finally be produced.

Thus, the

components necessary for the production of the immunoconjugates were in
place, and the synthesis and evaluation of these agents could begin (38).
Chemotherapeutic agents, such as methotrexate (15, 20, 33, 46, 55),
daunomycin, (31, 47, 66), daunorubicin (65, 67), and adriamycin
(doxorubicin), (56) were covalently attached to monoclonal antibodies
directed against various tumor antigens. Work was undertaken comparing
the biodistribution of two distinct chemotherapeutic agents, methotrexate
and daunom _-cin, that were conjugated separately to a monoclonal antibody
that reacts specifically with the osteosarcoma 791T.

These experiments

demonstrated that the conjugates were stable over the course of the threeday experiment. They also demonstrated a 100-fold increase in tumor levels
of the drugs in the conjugated treated animals over those seen in animals
treated with free drug. Further, an unrelated monoclonal antibody against
colon carcinoma HCT8 was conjugated with daunomycin and did not show
any targeting

~fficacy

in the osteosarcoma system (47) . Controls in which

methotrexate was conjugated to normal mouse IgG did not target the
chemotherapeutic agent to the tumor xenograft (46).
Monoclonal antibody-toxin conjugates have been used in attempts to
inhibit tumor growth in vitro and in vivo.

A variety of monoclonal

antibodies directed against a wide range of mouse and human tumor
antigens have been conjugated with ricin A chain (25, 49, 52, 57), diphtheria
toxin (11), gelonin (39, 54, 57), saporin (61), Pseudomonas exotoxin A (17),
and pokeweed antiviral protein (39, 49). Immunotoxins such as these exert
their effect on cells by binding to the antigen of interest, moving over the
surface of the cell until it is over a clatherin-coated pit, being endocytosed
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into an endosome, and eventually forming a lysosome and releasing the
toxin from the antibody inside of the cell (12). These immunotoxins have
for the most part been evaluated in vivo only against human tumor
transplants in mice or in mouse tumor models.

Results from these tests

have yielded results from no increase in mean survival time to 100%
protection from tumor development (18, 23).
Recently, one of the most promising immunotoxins, T101-ricin A chain
T101-RTA, composed of a monoclonal antibody directed against human COS
antigen conjugated with ricin A chain, underwent phase I trials in humans.
The study showed that the immunotoxin was reaching and binding to the
cells of interest, but that there was no sustained benefit in any of the patients
(n=4) tested. This was demonstrated to be due to the natural resistance of the
patients' leukemic cells that were refractile to in vitro treatment with T101RTA at levels >2000 ng/ml (29).
A similar approach to the development of a possible AIDS treatment,
using a portion of Pseudomonas exotoxin A hybridized to recombinant
human CD4, was shown to selectively kill HIV ::afected cells in vitro (14) .
This report reinforces the concept that the immunotoxins can be used for the
treatment of viral disease. Though this study was done in vitro, it is still
significant in that it demonstrates that targeted delivery of toxin molecules
to virally infected cells can take place and achieve the desired results.
The potential for using both drug-monoclonal-antibody and toxinmonoclonal-antibody conjugates for the treatment of cancer and viral
disease is exciting and full of possibilities. Essentially no work has been done
in the field of treatment of viral diseases with immunoconjugates.
Researchers have only now begun to investigate the possible application of
this approach to the treatment of viral disease, particulary with respect to the

18

AIDS epidemic. The gains that are currently being made in this field are
small but significant and are seminal in providing the groundwork for new
therapies for the treatment of viral, neoplastic, and genetic diseases.
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CHAPTER ill
A NEWLY DEVELOPED IMMUNOFLUORESCENT ASSAY
FOR DETERMINING THE PICHINDE VIRUSINHIBITORY EFFECTS OF SELECTED
NUCLEOSIDE ANALOGUES

An immunofluorescent assay (IFA) for Pichinde virus (PCV), a member
of the family Arenaviridae, was developed for antiviral drug assays against
the virus. The assay was performed by adding fluorescein-labeled anti-PCV
monoclonal antibody to virus-infected cells at 24 h after the ini•:al infection
and counting the infected cells with an epifluorescence microscope. The 50%
effective dose (EDso) for a series of nucleoside analogues tested against PCV
using this IFA was: 2-p-D-ribofuranosylselenazole-4-carboxamide
(selenazofurin),

<1.0~g/ ml;

(ribavirin), 6.0

~g/ml;

1-p-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

ammonium 1-13-D-ribofuranosyl-1,2,4-triazole-3-

carboxamide-5'-phosphate h ydra te (ribavirin-5'-monophosphate), 15.8
~g/ ml;

ammonium 1-13-D-ribofuranosyl-1 ,2,4-triazole-3-carboxamide-5'-

hemisuccinate (ribavirin-5'-hemisuccinate), 14.7

~g/ml;

ammonium 1-13-D-

ribofuranosyl-1,2,4-triazole-3-carboxamide-5'-(2,3-dimethyi)hemisuccinate
[ribavirin-5'-(2,3-dimethyi)hemisuccinate], 213.5

~g/ml;

ribofuranosyl-2-pyridone (3-deazauridine), 5.2
dihydroxypropyl)adenine, ([5]-DHPA), 471.0

~g/ml.

~g/ml;

4-hydroxy-1-13-Dand (5)-9-(2,3-

In comparison, the EDso

of ribavirin using inhibition of marginal PCV-induced cytopathogenic effect
after 12 days was 6.0
~g/ml,

tests.

~g/ml

and using plaque reduction after 5 days was 2.5

indicating that this IFA was of comparable sensitivity to these other
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The Arenaviridae family contains a group of viruses that have proven
to be serious human pathogens, with clinical signs of disease presenting as
hemorrhagic fevers.

Some members of this family of viruses, Junin,

Machupo, and Lassa (the etiological agents of Argentine hemorrhagic fever,
Bolivian hemorrhagic fever, and Lassa fever, respectively), are endemic in
some of areas of Africa and South America. Pichinde virus (PCV) is an
arenavirus from South America that is much less pathogenic to humans but
causes a very severe hemorrhagic disease in guinea pigs (8) and hamsters
(12).

Ribavirin has previously been shown to have in vitro and in vivo

antiviral activity against several of the arenaviruses (11, 16).
There has been an interest in developing a simple arenavirus antiviral
assay. Standard antiviral assays that depend upon plaque reduction (PR) or
inhibition of viral cytopathogenic effect (CPE) are not suitable for working
with PCV because this virus does not cause consistently quantifiable CPE
(13).

This report describes an immunofluorescence assay for use in

evaluating potential antiviral compounds against PCV. The assay is based
on enumeration of virus infected cells utilizing fluorescein-labeled anti-PCV
monoclonal antibody 24 h after exposure of cells to the virus. Utilization of
this assay as an antiviral test appears reproducible and provides the means to
rapidly screen many compounds while reducing both the sample size and
assay time.

L
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MATERIALS AND METHODS

Cells. The African green monkey kidney cells, Vero-76 cells, used in this
study were obtained from the American Type Culture Collection (Rockville,
MD) . Cells were passaged in minimum essential medium (MEM, GIBCO,
Grand Island, NY) supplemented with 9% fetal bovine serum (FBS, HyClone
Labs, Logan, UT) and 50 Jlg gentamicin/mi. For antiviral assays, cells were
seeded at 4 x 104 cells/well in 96-well polystyrene cell culture plates (Corning,
Corning, NY) and incubated at 37°C in humidified 5% C02 in air. The plates
were used 20-24 h after seeding.
Virus. PCV strain An 4763 was provided by Dr. Joseph D. Gangemi,
University of South Carolina School of Medicine, Columbia, SC.

Virus

stocks were prepared in Vero cells from twice plaque-purified PCV. The
virus was grown at 37°C and was harvested 2-3 days post-virus exposure,
aliquoted into ampules, and stored at -90°C until used. The virus stock used
in these experiments had a titer of 4 x 105 plaque-forming units (pfu)/ml.
The virus was also grown in the following cell lines:

KB, human oral

epidermoid carcinoma, HeLa markers, ATCC CCL 17; BHK, BHK-21, kidney
cells derived from one-day-old Syrian hamsters, ATCC CCL 10;

MDBK,

Madin-Darby bovine kidney cells, ATCC CCL 22; L, L929 cells, in growth
medium containing 10% fetal bovine serum rather than 10% horse serum;
L929, NCTC clone 929, mouse connective tissue cell line grown in media
supplemented with 10% horse serum, ATCC CCL 1; Vero, Vero-76, African
green monkey kidney, ATCC CRL 1587; MOCK, Madin-Darby canine kidney
cells, ATCC CCL 34; MRC-5, fetal male human lung diploid cells, ATCC CCL
171; WI-38, fetal female human lung diploid cells, ATCC CCL 75; LLCMK2D, rhesus monkey kidney, ATCC 7.1; HaK, adult Syrian hamster kidney
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cells, ATCC CCL 15; MA-104, embryonic African green monkey kidney cells,
passage 52 from Dr. Mary Estes, Baylor University, Houston, TX. This was
done in an attempt to find a cell line in which PCV would produce
consistently quantifiable CPE.

Antiviral compounds. Ribavirin
carboxarnide) and 3-deazauridine

(1-~-D-ribofuranosyl-1,2,4-triazole-3-

(4-hydroxy-1-~-D-ribofuranosyl-2-pyridone)

were provided by ICN Pharmaceuticals (Costa Mesa, CA). Selenazofurin

(2-~

D-ribofuranosylselenazole-4-carboxarnide) was provided by Dr. P. D. Cook,
Warner Lambert/Parke Davis, Inc. (Ann Arbor, MI) .
rnonophospha te (ammon ;urn

Ribavirin-5'-

1-~- D-ribofuranosy 1-1 ,2,4-triazole-3-carboxarn-

ide-5'-phosphate monohydrate), ribavirin-5'-hernisuccinate (ammonium 1~- D-ribofuranosy 1-1,2,4-triazole-3-car boxarnide-5'-hernisuccinate),

a virin-5'-(2,3-dirneth yl)hernisuccina te (ammonium

and rib-

1-~-D-ri bofuranosyl-

1,2,4-triazole-3-carboxarnide-5'-[2,3-dirnethyl]hernisuccinate) were synthesized in one of our laboratories (M.D.). The (5)-DHPA [(S)-9-(2,3-dihydroxypropyl)adenine] was provided by Dr. Erik De Clercq, Rega Institute for
Medical Research, Leuven, Belgium. All compounds were stored in sealed
vials at room temperature in the presence of dessicant. For antiviral testing,
the compounds were solubilized in MEM and then stored at 4°C until used.

Monoclonal antibodies. The hybridorna cell lines PC4.9A6 and PC4.9D3
were derived through the polyethylene-mediated fusion of FOX-NY
myeloma cells with the splenocytes from RBF/Dn mice. The spleen donor
mice had been hyperirnmunized with homogenized brain tissue in Freund's
adjuvant (Sigma, St. Louis, MO) from suckling RBF/Dn mice that had been
infected intracranially with PCV. The adenosine phosphoribosyltransferase
procedure as described by Taggart and Sarnloff (17) was used to select for
hybridorna cell lines.

The PC4.9A6 and PC4.9D3 hybridorna cell lines
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secreted anti-PCV monoclonal antibodies of the IgG2a subisotype. The two
monoclonal antibodies bind different epitopes of a PCV protein on PCVinfected cells. The hybridoma lines had been subcloned twice and the cells
were in the exponential growth phase when injected into recipient (BALB/c
x RBF/Dn) Ft mice that had been primed by intraperitoneal injection with
1:0 ml of 2,6,10,14-tetramethylpentadecane (pristane). The resulting ascites
fluids contained anti-PCV monoclonal antibodies at concentrations ranging
from 5-15 mg/ml.

Preparation

of

fluorescein-labeled

monoclonal

antibodies.

Immunoglobulins, predominantly monoclonal ant :bodies, were isolated
from ascites fluids by precipitation with ammonium sulphate and further
purified by affinity chromatography on protein A using the Bio-Rad Affi-Gel
Protein A MAPS II Kit (BIO-RAD Laboratories, Richmond, CA) .
Immunoglobulin samples were dialyzed against 0.1 M Na 2 HP04, pH 9.0.
Following dialysis, precipitates were removed by centrifugation for 15 min at
550 x g . Sufficient fluorescein isothiocyanate (FITC, Isomer 1 from Sigma
Chemical Co., St. Louis, MO) was added to result in a ; rotein to FITC wt:wt
ratio of 50:1 in the conjugation reaction mixture. The FITC was added as a
solution containing 1.0 mg/ml of FITC dissolved in 0.2 M Na 2 HP0 4, pH 9.0;
this FITC solution was prepared just before addition to the immunoglobulin.
The conjugation of fluorescein to protein was then accomplished by bringing
the pH of the immunoglobulin-FITC mixture to 9.5 by dropwise addition of
0.2 M Na3P04 and allowing the reaction to proceed at 25°C for 2.5 h. The
conjugation conditions were selected to yield a fluorescein to protein ratio in
the final conjugate of approximately 10 fluorescein molecules per molecule
of immunoglobulin (4). The unconjugated FITC was removed by dialysis
against Dulbecco's phosphate-buffered saline: 0.5 mM MgC1 2, 2.7 mM KCl, 1.5

~
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mM KH2P0 4 , 8 mM Na2HP04 and 140 mM NaCI, pH 7.2 (PBS), containing
0.1% sodium azide.

The fluorescein-labeled monoclonal antibody

preparations were then further purified by gel exclusion chromatography on
Sephadex G-75 (Pharmacia Fine Chemicals, Piscataway, NJ). The resulting
fluorescein labeled monoclonal antibody preparations were titered in a direct
immunofluorescent cell assay using PCV-infected Vero cells.

There was

only the slightest nonspecific staining at dilutions of 1:100 or greater, while
the specific staining was very clear and intense out to dilutions of at least
1:1,600.
Immunofluorescence assay for PCV-infected

~ells.

The IFA for PCV-

infected cells used a cocktail of fluorescein-conjugated murine monoclonal
antibodies towards PCV designated PC4.9A6 and PC4.9D3. These were diluted
to approximately 0.01 to 0.03 mg protein/ml and then combined in equal
volumes in PBS prior to use. Unused antibody was kept frozen at -20°C until
thawed immediately prior to use. At 20-24 h postinfection (p.i.), the medium
was removed from the wells of the 96-well plates and the cells were allowed
to dry thoroughly at room temperature. If the cell she_ts were not allowed to
dry thoroughly prior to adding the 80% acetone fixative, many of the cells
would detach from the well during the fixation and staining procedures.
The cells were then fixed in 80% acetone by adding cold distilled water (50
Jll/well) followed by immediate addition of

cold (-15°C) acetone (200

J.!l/well) to the water in each well. If the acetone and water were mixed prior
to addition to the wells, or if the acetone was added first, the plastic was
etched, thus spoiling the specimens for microscopic examination.

The

fixation was allowed to proceed for 5 minutes and then the fixative was
poured from the plate and the cell sheets were allowed to dry thoroughly.
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Cells were either immunostained immediately after drying or stored at
-l5°C.
Fluorescein-labeled monoclonal antibody towards Pichinde virus was
used at a dilution of 1:500 to provide intense specific staining with only
minimal nonspecific background.

For immunostaining, 50 111 of the

fluorescein labeled antibody was added to each well and immunostaining
was allowed to proceed at 37°C for 1-2 h before the immunostain was poured
from the plate. The plate was inverted on absorbent paper and allowed to
drain, a drop of mounting medium (5) was added, and immunostained cells
were viewed through the bottom of the plate using a 16X objective and lOY
eyepieces on a Zeiss epifluorescence microscope. The number of fluorescent
cells in one strip across the center of each well was counted and the total
fluorescent cells per well determined as described by Barnett et a!. (2) and Tu
eta!. (18). The multiplication factor calculated for the one strip counts in this
study was 6.36.
Immunofluorescence antiviral assay (IFA) and toxicity evaluation.

Growth medium was aspirated from confluent monolayers of Vero cells
growing in 96-well culture plates and 100 111 of PCV diluted in MEM with 2%
FBS was added to the appropriate wells. The virus inoculum was such that
there were approximately 10 fluorescing cells per microscope field in virus
control wells, the multiplicity of infection (MOl, the ratio of infectious virus
to cells) was approximately 0.002. The virus was allowed to adsorb for 30
minutes at room temperature after which time 100 111 of test compound
diluted in MEM was added without removing the virus inoculum. Seven
concentrations of test compound were used: 1000, 320, 100, 32, 10, 3.2 and 1
1-!g/ml. The plates were then sealed with plastic wrap (Saran Wrap™, Dow
Chemical Corp.) and incubated for 20-24 h at 37°C. The cells were fixed and
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immunostained to detect PCV-infected cells as described above. The number
of fluorescing cells in treated wells was determined and compared to the
number of fluorescing cells in wells without drug.

Each assay included

toxicity controls as well as virus and normal cell controls similar to a virus
reduction assay described previously (15). Three virus-containing wells were
used for each dose, with one additional well being used for toxicity controls
(cells + sterile virus diluent + drug). Six wells on each plate were used for
normal cell controls (cells + sterile virus diluent + drug diluent).

Six wells

on each plate were used for virus controls (cells +virus + drug diluent). The
antiviral activity was expressed as the 50% effective dose (EDso), which was
the concentration of drug required to reduce the number of fluorescing
infected cells by 50%. The EDso was determined by plotting the percent
inhibition versus compound concentration on a semilogarithmic chart.
Drug toxicity was evaluated by examining the toxicity control cells
microscopically for morphological changes, when compared with normal
cell controls.

The 50% cytotoxic dose (CD 50 ) was defined as that

concentration which caused approximately a 50% change in cellular
morphology of toxicity control cells.

This toxicity determination, while

subjective and approximate, was based on graded morphological changes
observed at increasing levels of the test compounds, with 0% representing
no morphological change and 100% representing total cell destruction. The
therapeutic index (TI) is defined as the CDso/ED50.
Inhibition of cytopathogenic effect and plaque reduction assays.

Ribavirin was run in side by side assays in order to compare the sensitivity of
the immunofluorescence antiviral assay to the more standard antiviral
assays such as inhibition of viral CPE (15) and the PR (6) assays. In the CPE
assay, the drug was added in triplicate to wells of a 96 well plate in one-half
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log10 dilutions from 1000

~J.g/ml

to 1.0

~J.g/ml.

The plates were then scored

when virus controls reached a maximum level of CPE. In these studies
using PCV at an MOl of 0.001 this did not occur until approximately 12 days
after virus infection and the maximum CPE was considered to be 1+. In the
PR assay the test compound was incorporated into the overlay media and
was then placed onto infected cell monolayers in 6-well plates .

The

monolayers in this assay were infected at an MOl of 0.0001. After 5 days of
incubation, the plaques in the treated wells were counted and compared with
those of the virus control wells.

RESULTS

Attempts to find a cell line in which PCV would produce consistent and
quantifiable CPE. Several cell lines, noted in Materials and Methods, were
used in an attempt to find a cell line that produced consistently quantifiable
CPE when infected with PCV. This was done in order to use the inhibition
of C:?E assay (15) that is used as a standard antiviral screening test in this
laboratory. Only one cell line, Vero-76, showed slight viral CPE, in this case
appearing 12 days p.i. PCV did not produce adequate CPE in any of the other
cell lines that were tested.
Antiviral activity of ribavirin, 3-deazauridine, (S)-DHPA, and ribavirin
derivatives against PCV.

An example of an antiviral test using the IFA

procedure is seen in Table 1. Ribavirin was used as the test compound.
Toxicity controls exhibited morphologic changes only at 1000 and 320 !!g/ml
dose levels; the CDso was determined to be 1000

~J.g/ml.

Exposure of the

infected cells to ribavirin resulted in total inhibition of fluorescent cells at 10
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through 1000 !J.g/ml dosage levels; a 43% inhibition of infected cells was seen
at 3.2

~J.g/ml.

The TI for ribavirin was calculated to be 217.4 in this test.

Using the IFA procedure, the compounds described earlier were
evaluated against PCV.

The virus was found to be most sensitive to

selenazofurin (Table 2). The data also indicate that selenazofurin had the
greatest TI of the compounds tested . Ribavirin-5'-hemisuccinate and, as
described above, ribavirin were very effective against PCV using this assay.
In contrast, methyl groups incorporated at the 2- and 3- positions of the
hemisuccinate side chain reduced

the TI 21-fold .

Ribavirin-5 '-

monophosphate and 3-deazaurid:Tle were also active against the virus. Very
weak activity against PCV was seen with (5)-DHPA.
The infected cells were easily distinguished from uninfected cells by the
bright apple green fluorescence of the immunostain. There was virtually no
background staining of the uninfected cells. The stain appeared to bind to
the membrane and cytoplasmic components of the fixed, infected cells. The
nuclei of the infected cells did not appear to bind any immunostain. This
pattern would be consistent with

~he

replication and maturation of PCV

particles in the cytoplasm and their budding through of the cytoplasmic
membrane of infected cells.
Comparison of IFA with inhibition of viral CPE and PR antiviral assays.
A comparison of the IFA to the inhibition of viral CPE and PR assays is
shown in Table 3. The IFA sensitivity appeared comparable to that of the
other two assays used although the PR assay appears to be slightly more
sensitive than the IFA or the inhibition of viral CPE assay. This may be, in
part, due to the relative MOl's used in the different assays, with the PR assay
being infected with 10-20-fold less virus than the inhibition of viral CPE or
IFA assays, respectively. Also, the PR assay required larger amounts of the

36

compound than either IFA or CPE procedure and the time to endpoint was 4
days longer that that required in the IFA test.

DISCUSSION

The IFA procedure described here appears to be an acceptable tool for
antiviral drug testing. By comparing the results obtained from evaluating
the antiviral efficacy of ribavirin using several different antiviral assays, the
IFA demonstrates several important advantages: 1) The IFA is essentially as
sensitive as either of the other assays used in this stuc y,

2) it has the

advantage of requiring much less compound than the PR assay,

3) the

endpoint is much less ambiguous than that of the CPE assay in which
reproducible, readily discernible PCV-induced CPE was difficult to achieve,
and

4) the IFA assay can be performed in 24 h instead of the 5-12 days

required for PR testing or CPE inhibition, respectively.

The procedure

worked well for evaluation of all nucleoside analogues used in this study.
The relative costs of the three assays used in this study ar._ comparable, if
the production costs of the monoclonal antibodies are not taken into
consideration. This procedure can be adapted for use as an indirect method
using virus-specific polyclonal sera and FITC-labeled secondary antibody.
The monoclonal antibodies to PCV produced in our laboratories that were
used for this study are not available commercially.
The results reported here indicate that PCV is reasonably sensitive to
selenazofurin,

ribavirin,

ribavirin-5 '-hemisuccinate,

monophosphate, and 3-deazauridine.

ribavirin-5'-

Selenazofurin and ribavirin have

previously been reported active against PCV using PR tests (10), and
ribavirin has also exhibited in vivo efficacy against this virus (7).

3-

~

I
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Deazauridine is known to inhibit a number of other RNA viruses, including
rhino, influenza A and B, parainfluenza 1, and vesicular stomatitis viruses
(9), as well as Gross and Rauscher murine leukemia viruses (14). Ribavirin5'-monophosphate exhibited both in vitro and in vivo efficacy against
influenza A and B and murine hepatitis viruses (1).

The aliphatic

nucleoside (S)-DHPA has been reported to have a broad-spectrum antiviral
activity (3) although prior to these experiments it had never been tested
against PCV. The results of testing (S)-DHPA against PCV indicate that the
compound was active only at the highest concentrations. This is the first
report of antiviral testing with the other ribavirin derivatives described here.
The loss of activity associated with the incorporation of methyl groups at the
2- and 3- positions of the 5'-hemisuccinate of ribavirin indicates that steric
hindrance may inhibit either the transport of the molecule into the infected
cell or, more likely, the hydrolysis to free ribavirin.

~

I
I
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TABLE III-1. Effect of ribavirin against Pichinde virus infection in Vero
cells as determined by IFA procedure.
Fluorescent
Cone.
(!lg/ml)

Cytotoxicitl

1000
320
100
32
10
3.2
1.0
0

(%)

cells
(No. of cells I well)

50
25
0
0
0
0
0
0

0, 0, 0
0, 0, 0
0, 0, 0
0,0,0
0,0, 0
133,89,57
127, 146, 147
171,235,178,114,173,102

Mean

Inhibition

fluorescentof fluorescent
cells/well
cells (%)
0
0
0
0
0
93
140
162

100
100
100
100
100
43
14
0

EDsob: 4.6!-lg/ml
CDsoc: 1000 !lg/ml
Tid: 217.4
a As determined by microscopic examination of toxicity control wells,
expressed as enlarged, flattened cells. The percent indicated is the
approximate degree of enlargement and flattening that occurred.
b EDso: 50% effective dose, determined by plotting concentration of drug
versus percent inhibition on a semilogarithmic chart.
c COso: 50% cytotoxic dose as determined by microscopic examination of
toxicity control wells.
d Therapeutic index= CDso/EDso.
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TABLE III-2. Activity of nucleoside analogues against PCV as measured by
IFA procedure.
EDso

a

()lg/ml)

Drug
Selenazofurin
Ribavirin
Ribavirin-5'-hemisuccinate
Ribavirin-5' -monophosphate
3-Deazauridine
Ribavirin-5'-(2,3-dimethyl)
hemisuccinate
(S)-DHPA

•

COso
()lg/ml)

Tic

<1.0
6.0
14.7
15.8
5.2

320
1000
>1470
>1000
320

>320.0
166.7
>100.0
>63.3
61.5

213.5
471.0

>1000
>1000

>4.7
>2.1

a EDso: 50% effective dose, determined by plotting concentration of drug
versus percent inhibition on a semilogarithmic chart; each is an average
of 1 to 4 experiments.
b COso: 50% cytotoxic dose.
c TI = CDso/ED50

~

I
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TABLE III-3. Activity of ribavirin against PCV as measured by different
antiviral assays in Vero cells.

Antiviral Assaya

EDso
(J.!g/ml)b

CPE
PR
IFA

3.2-10
1.0-3.2
3.2-10

Time to
Amt. required/
assay (mg)c endpoint (days)d
5
50
5

12

5
1

a CPE =inhibition of cytopathogenic effect; PR =plaque reduction; IFA =
immunofluorescence assay.
b EDso's expressed as ranges, from multiple experiments.
c Amount of compound required to make initial stock of 2000 J.!g/ml.
d Time at which results could be determinec .
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CHAPTER IV
CHARACTERIZATION OF MONOCLONAL ANTIBODIES
PRODUCED AGAINST PICHINDE VIRUS

Mouse monoclonal antibodies directed against Pichinde virus (PCV)
were produced to evaluate their possible application as vehicles for the
directed delivery of antiviral drugs or toxins to virus infected cells.
Monoclonal antibodies PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 were of the
IgG2a subisotype and reacted with both acetone-fixed and live PCV-infected
Vero-76 cells .

Radioimmunoprecipitation of proteins from 35S-

m e thionine-labeled PCV-infected cell lysates with PC4.9A6, PC4.9D3,
PC4.7C2, PC4.8D2, and hyperimmune hamster serum showed that all the
antibodies precipitated two different PCV proteins, one of 64,000 daltons,
and another of 38,000 daltons.

These proteins were, respectively, PCV

nucleoprotein (NP) and a breakdown product of NP that was present in
PCV-infected cells.

Fluorescein-labeled PC4.9A6 (FITC-9A6) reacted

optimally with PCV-infected acetone-fixed cells and did not stain
noninfected cells. The staining of live PCV-infected cells with FITC-9A6
revealed that >90% fewer infected cells were stained than were observed in
similarly infected cells that were acetone-fixed prior to staining. Live PCVinfected cells stained with FITC-9A6 appeared more rounded up and
refractile than acetone-fixed PCV-infected cells.

Both PCV-infected and

noninfected live cells demonstrated some non-specific staining with FITC9A6, although this staining was readily discernible from the virus-specific
staining. In vivo stained splenic macrophages derived from PCV-infected
hamsters that had been injected with FITC-9A6 demonstrated a 400%
increase in total fluorescence over similarly treated, non-infected cells when
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analyzed by flow cytometry. This was an indication that FITC-9A6 does
have some ability to specifically target PCV-infected cells in vivo and that it
warrented further investigation into its use as a delivery vehicle for the
directed delivery of either antiviral compounds or toxins.

Arenaviruses are the etiological agents of several significant
hemorrhagic diseases in humans, namely, Lassa fever, Argentine
hemorrhagic fever, and Bolivian hemorrhagic fever.

These diseases are

spread by rodents that are asymptomatic carriers of the virus. These rodents
shed large

amount~

ot virus in their urine. Disease outbreaks most often

occur in lesser developed areas of Africa and South America where it is
often difficult to limit the contact between rural households and the rodents
that harbor these pathogenic viruses.
Although ribavirin

(1-~-D-ribofuranosyl-1 ,2,4-triazole-3-carboxamide)

has been shown to be effective in reducing the mortality of patients
hospitalized with severe, acute Lassa fever there still exists a significant
number of patients ·. :ho are not responsive to ribavirin therapy (10).
Similar observations have been made using animal models of Argentine
and Bolivian hemorrhagic fevers (7).

Treatment of similarly infected

individuals with immune plasma from patients with Lassa fever resulted
in only slightly diminished mortality rates (7). Currently, more effective
means of clinical intervention in arenaviral hemorrhagic diseases are
needed in the areas of the world where these diseases are endemic.
One method of enhancing the effectiveness of a drug or toxin is to target
its delivery to the cell population of interest, whether in neoplastic or in
virally induced diseases (2, 4, 12). Monoclonal antibodies were produced
that were reactive with PCV-infected cells (1). This study reports on the
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suitability of these monoclonal antibodies as possible vehicles for the in
vivo delivery of antiviral compounds or toxins to PCV-infected cells in
MHA hamsters.

MATERIALS AND METHODS

Cells. The Vero-76 cells used in this study were obtained from the
American Type Culture Collection (Rockville, MD) .

The cells were

passaged in minimum essential media (MEM, GIBCO, Grand Island, NY)
supplemented with 9% fetal bovine serum (FBS. Hyclone Labs, Logan, UT).
For immunofluorescent assays in 96-well polystyrene plates (Corning,
Corning, NY), 0.1 ml of cells diluted to a density of 4 x 105 cells/ml in MEM
with 9% FBS was added to each well. Similar immunofluorescent assays
were done using glass cover slips seeded with 0.3 ml of the same density of
Vero-76 cells.
Virus. PCV strain An 4763 was provided by Dr. Joseph D. Gangemi,
University of South Carolina School of

Medici:: ~,

Columbia, SC.

Virus

stocks were prepared in Vero cells from twice plaque-purified PCV. The
virus was grown at 37°C and was harvested 2-3 days after virus exposure,
aliquoted into ampules, and stored at -90°C until used. The virus stock had
a titer of 4 x 105 plaque-forming units (pfu)/ml and an immunofluorescent
titer of 5 x 106 fluorescent foci-forming units/ml when stained with a
PC4.9A6-fluorescein conjugate.
Animals. The MHA hamsters used in this experiment were supplied by
Charles River Laboratories, Inc. (Wilmington, MA).

The hamsters were

females of >10 weeks of age and weighed approximately 60-70 gat the onset
of the experiment. The animals were quarantined for at least 24-48 h prior to
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use. The hamsters were housed five per cage in polycarbonate cages with
corn cob bedding and were provided with Wayne Lab Blox and tap water ad
libitum.
Monoclonal antibodies.

Monoclonal antibodies PC4.9A6, PC4.9D3,

PC4.7C2, and PC4.8D2 were produced against PCV as previously described
(1) . Monoclonal antibody 33.6, reactive with an epitope on glycoprotein 2
(GP2) that is conserved amongst all the arenaviruses, was provided by
Micheal J. Buchmeier, Scripps Institute of Immunology, La Jolla, CA (18).
Isotyping of monoclonal antibodies.

The monoclonal antibodies

PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 were isotyped and subisoty .•ea
using a mouse antibody isotyping kit from Hyclone Laboratories (Logan,
UT), as p er manufacturer's instructions.

Briefly, the kit was a sandwich

ELISA done in a 96-well microtiter plate using a-phenylenediamine as the
horseradi sh peroxidase (HRPO) enzyme substrate. The microtiter plates
were read at 490 nm on a Bio-Tek (Winooski, VT) microplate reader.
Normal mouse serum (NMS) was used as a positive control.
Radioimmunoprecipitation of Pichinde virus antigens. Pichinde

viru~

infected Vero-76 cells were labeled with 25-50 ~Ci/ml of Tran35S-label®
(ICN Biomedicals, Inc., Irvine, California), a cellular hydrolysate of

Escherichia coli grown in the presence of carrier-free 35S04=. This product
contained 70 % L-methionine, 15 % L-cysteine, and various non-labeled
amino acids as described in the accompanying product literature. Infected
and noninfected cells were methionine-starved with methionine-deficient
media for 2 h prior to addition of the radiolabel. The cells were labeled at
various times, typically at 36 h post-infection (p. i.), for 2-18 h, after which
they were chased with media containing a 100-fold excess of cold
methionine .
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Infected and noninfected cells were harvested by scraping them from
the flasks and pelleting them by centrifugation at 7500 x g. The cell pellets
were resuspended in lysis buffer (0.1 M Tris, pH 8.0, 0.14 M NaCI, and
0.025% sodium azide [TSA] with 1% Triton X-100, 1% bovine hemoglobin, 1
mM iodoacetamide, 0.2 U aprotinin and 1 mM phenylmethylsulfonyl
fluoride, [PMSF]) and were kept at 4°C for 1 h. After lysis of the cytoplasmic
membranes the nuclei were pelleted by centrifugation and the supernatant
containing solubilized membrane proteins and cytoplasmic components
was collected and frozen in aliquots at -90°C.
Prior to the immunoprecipitation of the radiolabeled antigens with the
relevant monoclonal antibodies, the cell lysates were cleared with an
irrelevant ascites fluid containing an IgG2a monoclonal antibody produced
against an unrelated bacterial antigen. This reduced the nonspecific binding
of the components of the cell lystate to the relevant monoclonal antibodies.
The irrelevant ascites fluid was added to the cell lysates and incubated for 1
hat 4°C. The nonspecific complexes were precipitated by addition of 50-100
Jll of 10% suspension of Staphylococcus aureus Cowan strain II (Staph A)
cells to the pretreated cell lysates. These cells express protein A on their
surfaces. Protein A has a high affinity for the Fe portion of mouse IgG2a
immunoglobulin molecules and can be used to precipitate antigen-antibody
(Ag-Ab) complexes. The hybridoma cell culture fluids that contained the
relevant monoclonal antibodies, PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2
were added to the precleared cell lysates, containing 106 counts per minute
of radiolabel, and were incubated for 1-2 h at 4°C. The Ag-monoclonal
antibody complexes were then precipitated by adding SO Jll of Staph A cells
that had been washed twice with lysis buffer. The complexes were pelleted
by centrifugation for 5 seconds in a microfuge (3000 x g, Hermie model
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Z230A, National Labnet Co., Woodbridge, NJ). The Staph A-monoclonal
antibody-antigen complexes were washed twice in cold dilution buffer (0.1%
Triton X-100, and 0.1% bovine hemoglobin in TSA), once in cold TSA
buffer, and once in cold 0.0625 M Tris-Cl, pH 6.8. The pelleted complexes
were resuspended in 2x sample buffer (0.125 M Tris-Cl, pH 6.8, 4% SDS, 20%
glycerol, 1 mM dithiothreotol [OTT), and 0.001% bromophenyl blue) and
boiled for 3 min to dissociate the radiolabeled antigen from the complex.
The Staph A cells were again pelleted by centrifugation and the supernatant,
containing the now dissociated protein of interest, was immediately loaded
onto a 10% polyacrylamide gel for electrophoresis (13).
Polyacrylamide gel

electrophoresis.

Sodium dodecyl sulfate-

polyacrylamide gel electrophoresis (SD5-PAGE) was performed as described
by Laemmli (8). Samples for electrophoresis were solublized by boiling
them for 3 min in 2x sample buffer or in 2x nonreducing sample buffer that
did not contain any reducing agent such as OTT or p-mercaptoethanol.
Samples were loaded on to a discontinuous polyacrylamide gel consisting of
a 4% stacking gel (final concentrations: 4% total [T] acrylamide 2.7%
crosslinked [C] acrylamide, 0.1% SDS, and 0.125 M Tris-Cl, pH 6.8) poured
over a 10% separating gel (final concentration: 10%T 2.7%C acrylamide,
0.1% SDS, and 0.375 M Tris-Cl, pH 8.8). The gel apparatus was filled with
tank buffer (0.025 M Tris-Cl, pH 8.3, 0.192 M glycine, and 0.1% SDS) and the
solublized samples were loaded into the appropriate wells. A constant
current of 20 rnA per gel was applied until the bromphenol blue tracking
dye reached the bottom edge of the gel. Molecular mass markers
(Diversified Biotech, Newton Centre, MA, molecular mass [m.m.] range
12,700- 95,000 daltons) suitable for silver staining were included on the gels
that were silver stained.

14C-Radiolabeled m.m. standards (Bethesda
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Research Laboratories Life Technologies, Inc., Gaithersburg, MD, m .m .
range 14,300- 200,000 daltons) were included in the gels that were used for
fluorography. The gels were fixed in 10% (v /v) glacial acetic acid and 30%
(v /v) methanol, treated with FluroHance (Research Products International
Corp., Prospect, IL) according to manufacturer's instructions, dried and used
to expose Kodak X-0-Mat X-Ray film, silver stained as described below, or
used for electrophoretic transfer of the separated proteins to nitrocellulose
for use in immunodetection.
Silver staining of polyacrylamide gels. Polyacrylamide gels (0.75 mm
thick) were fixed in 10'f. (v /v) glacial acetic acid and 30% (v /v) methanol
overnight and washed (3 x 10 min) in 5% (v /v) glacial acetic acid and 10%
(v /v) methanol to further remove any residual SDS. The gels were soaked
in 0.3 mM potassium dichromate and 0.0032 N nitric acid for 5 min. The
gels were washed (4 x 30 sec) in deionized water. The gels were placed in a
solution of 0.12 M silver nitrate for 25 min under ambient light. The silver
nitrate solution was decanted and the gels were washed quickly twice with
0.28 M sodium carbona• 2 and 0.05% (v /v) formalin .

The gels were

d eveloped in a third wash of this mixture until the bands reached the
desired intensity. Development of the gels was stopped by immersing the
gel in a solution of 1% acetic acid. The silver stained gels were dried onto
paper backing.
Immunodetection of proteins in cell extracts. Extracts of cells infected
with PCV at an multiplicity of infection (MOl) of 0.1 and noninfected cells
were prepared by the addition of lysis buffer containing 0.1 M Tris, pH 8.0,
0.5% Triton X-100, 1 mM iodoacetamide, aprotinin (0.2 U/ml), and 1 mM
phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis, MO) at 4°C for 1
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h . The nuclei were then pelleted by centrifugation and supernatants were
aliquoted into vials and stored at -90°C until used.
PCV-infected and noninfected cell lysates were subjected to SDS-PAGE
prior to being transferred onto nitrocellulose employing the procedure of
Towbin et a!. (14) . Proteins reactive to the monoclonal antibodies were
detected using Auroprobe BLplus® (Janssen Biotech N . V., Piscataway, NJ)
according to manufacturer's instructions. Total cell lysates were stained
with AuroDye Forte® (Janssen Biotech) as per manufacturer's instructions.
Detection of viral and cellular glycoproteins.

Viral and cellular

glycoproteins were detected on the electrophoretic nitrocellulose transfers of
the PCV-infected and noninfected cell lysates using a method described by
Clegg (3). Briefly, the blots were blocked with a solution of 2.5% bovine
serum albumin (BSA) in PBS for 1 h at room temperature with agitation
after which they were incubated in a solution of concanavalin A (Con A, 10
J.tg/ml, Sigma, St. Louis, MO) in phosphate-buffered saline (PBS, Sigma, St.
Louis, MO) with 0.5% Triton X-100 (Sigma, St. Louis, MO) for 1 h at room
temperature with agitation. The transfers were

w ~J hed

(5 x 5 min) with

washing buffer (PBS with 0.5% Triton X-100). The blots were incubated in a
solution of HRPO (50 Jlg/ml, Sigma, St. Louis, MO) for 1 h at room
temperature with agitation. The blots were again washed (5 x 5 min) with
washing buffer.

The viral and cellular glycoproteins were detected by

incubating the transfers in a solution of 3,3'-diaminobenzidene (DAB, 0.5
mg/ml, Sigma, St. Louis, MO) in Tris-Cl buffer, pH 7.6, with 0.04% NiCl2
and 0.004% H202. Development was stopped by immersion of the blots in
deionized water.
Comparison of the binding of FITC-labeled PC4.9A6 monoclonal
antibody to fixed and non-fixed PCV-infected cells. Vero-76 cells were
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seeded onto glass cover slips in Petri dishes at a density of 1.2 x 105
cells/ cover slip. At 24 h after the cover slips were seeded, the confluent
cultures were infected with PCV diluted in maintenance medium (MEM
with 2% FBS, 0.1% NaHC03, and 50 jlg gentamycin/ml). At 48 h p.i., the
cells were either fixed with acetone for 5 min and stained with 6 jlg/ml of
FITC-labeled PC4.9A6 conjugate or stained alive by diluting the PC4.9A6FITC conjugate directly into the maintenance medium at the same
concentration. All cells, acetone-fixed or alive, were stained for 3 h with the
conjugate after which they were rinsed with Evan's Blue stain in PBS and
mounted onto a glass slide with a drop of elvanol mounting medium (6).
The cells were then observed and photographed immediately under 400x
magnification employing both Hoffman contrast and epifluorescent optics
using a Nikon Diaphot microscope.
In vitro targeting of PCV-infected spleen cells by FITC-labeled PC4.9A6
monoclonal antibodies Two groups of MHA hamsters, PCV-infected (n=4)
and noninfected (n=5), were used to investigate the in vitro targeting of the
FITC-labeled PC4.9A6 conjugate to PCV-infected spleen cells.

Infected

hamsters used for in vitro targeting were infected subcutaneously (s.c.) with
10 LDso units of PCV. Noninfected hamsters were included as controls.
Both infected and noninfected hamsters in the in vitro targeting study
were sacrificed on day 9 p.i. by cervical dislocation and their spleens were
removed. The spleens were placed into 10 ml of Puck's balanced salts
solution and a spleen cell suspension was made using a Stomacher
laboratory apparatus (Tekmar Co., Cincinnati, OH). The cell suspension was
pelleted by gentle centrifugation and the contaminating red blood cells were
lysed by hypotonic shock by suspending the pellet in 9 ml of water for 10
seconds after which 1 ml of lOx PBS was added to the suspension. The
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remaining cells were pelleted and washed twice in RPMI 1640 with 15%
FBS. Prio~ to staining, 106 cells were aliquoted into a test tube and the
samples were pelleted by centrifugation and resuspended in 1 ml of RPMI
1640. Cells were stained for 1 h at room temperature with 60 J.lg/ml of FITClabeled PC4.9A6 after which the macrophage population of the spleen cell
suspension was subjected to flow cytometry analysis using a Coulter
Electronics (Hialeah, FL) EPICS flow cytometer.
In vivo targeting of PCV-infected spleen cells by FITC-labeled PC4.9A6
monoclonal antibodies in MHA hamsters.

PCV-infected (n=4) and

noninfected (n=S) hamsters from the in vivo targeting groups were injected
i.p . with 0.5 ml of 60 J.lg/ml FITC-PC4.9A6 conjugate on day 9 p.i., 8 h prior
to being sacrificed. Hamsters in both groups were sacrificed by cervical
dislocation, the spleens were removed, and spleen cell suspensions were
prepared for flow cytometry as described above except that the suspensions
were not subjected to any further staining at anytime during the
experiment. Spleen cell suspensions were then subjected to flow cytometry
analysis as described below.
Flow cytometry analysis of in vivo and in vitro stained hamster spleen
cell suspensions. Flow cytometry was performed with an EPICS-C flow
cytometer (Coulter Electronics Inc., Hialeah, FL), equipped with an argon
laser tuned to 400 mW at the 488 nm line. Cells were carried in Isoflow
sheath fluid (Coulter) through a 76 micron tip. Fluorescence data for FITC
were obtained using a bit-map format, gated on the forward light scatter
versus right-angle light scatter histogram. The bit map was used to isolate
cells of interest, splenic macrophages, and to exclude debris and doublets.
Fluorescent signals were processed through a three-decade log amplifier and
displayed on a 256-channel scale. Fluorescence intensity was standardized
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using 10 Jlm latex beads (Immunocheck, Coulter) and adjusting the laser
power to place the log-green histogram in channel 119.

Other settings

remained constant for all samples. Data were stored and later analyzed
using the Cytologic® software package (Coulter).

RESULTS

Subisotype of anti-PCV monoclonal antibodies. Monoclonal antibodies
PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 were found to be of the IgG2a
subisotype (Table 1).
Staining of acetone-fixed and live PCV-infected and noninfected Vero76 cells using FITC-labeled PC4.9A6 monoclonal antibody. When acetone
fi xed PCV-infected Vero-76 cells were stained with FITC-conjugated
PC4.9A6 and viewed under epifluorescence optics there was intense, applegreen virus-specific fluorescent staining observed. Usually 30-50 infected
cells were present in areas of fluorescence which appeared to overlap in
many of the regions of the coverslips (Fig. 1A).

The acetone-fixed

noninfected cell controls showed no virus specific staining and very little
background staining (Fig. 1 B) .

Using Hoffman contrast optics, no

morphological or pathological distinctions were observed between the
acetone-fixed PCV-infected cells and the noninfected cells (Figs. 1C and 10,
respectively).
When live, unfixed, PCV-infected cells that had been stained with FITClabeled PC4.9A6 were observed using epifluorescence optics virus-specific as
well as some nonspecific staining was observed. The virus-specific staining
observed was similar to that seen with the acetone-fixed cells, except that
the specifically stained areas contained only a few (1-5) fluorescent cells (Fig.
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2A). When the same field was viewed using Hoffman optics, the cells that
were fluorescing appeared much more rounded-up and more refractile (Fig.
2C) than the cells that had been acetone-fixed prior to staining (Fig. lC).
Nonspecific staining occurred in both the infected and noninfected cells
and was characterized by an even, diffuse, light green fluorescence of entire
individual cells. There was only one cell per foci that took up the stain in a
nonspecific manner (Fig. 2B) . This staining faded rapidly under the UV
light, and no longer fluoresced within 30 to 90 seconds of being placed in the
UV beam of the microscope. There were no morphological differences
observed in the cells tha : demonstrated nonspecific staining in either the
infected or noninfected groups when observed under Hoffman optics
(Figures 2C and 2D, respectively).
Characterization of the PCV peptide binding specificity of the anti-PCV
monoclonal antibodies.

The monoclonal antibodies PC4.9A6, PC4.9D3,

PC4.7C2, and PC4.8D2 were used to immunoprecipitate 355-methioninelabeled peptides from PCV-infected cell lysates. Monoclonal antibody 33.6,
hyperimmune hamster sen: .:l (HHS), and an unrelated hybridoma ascites
fluid (FOX-NY) were included as positive (33.6 and HHS) and negative
(FOX-NY) controls, respectively. Monoclonal antibodies PC4.9A6, PC4.9D3,
PC4.7C2, and PC4.8D2 all immunoprecipitated the same viral peptides, a
64,000 dalton protein, and a 38,000 dalton protein (Fig. 3). HHS reacted with
the same two viral peptides.

Monoclonal antibody 33.6, specific for an

epitope on GP2 that is conserved amongst all arenaviruses (17), did not
precipitate any virus proteins in this assay. The negative control FOX-NY
also did not precipitate any arenavirus proteins. None of the antibody
preparations precipitated proteins from noninfected Vero-76 celllysates.
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Detection and localization of PCV glycoproteins on nitrocellulose from
electrophoretic transfers of PCV-infected and noninfected cell lysates.
Glycoproteins present in both PCV-infected cells and noninfected cells were
detected using a Con A-HRPO detection system (3). This system is based on
the ability of the divalent lectin Con-A to bind to the glycoproteins
immobilized on the nitrocellulose membrane and also to the HRPO
detection enzyme that is also a glycoprotein. Using this system, only the
glycoproteins present in the lysates were detected and localized on the
nitrocellulose membrane.

In the lane containing the PCV-infected cell

lysate (lane 3 of Fig. 4) there were two bands that d0 not appear in the lane
containing the noninfected cell lysate (lane 4 of Fig. 4) . These two bands
that were unique to the PCV-infected cell lysate are glycoproteins (GPl and
GP2) of 57,000 daltons and 33,000 daltons in size. Monoclonal antibody 33.6
reacted with the 33,000 dalton glycoprotein (GP2) in the PCV-infected cells
lysate (lane 2 of Fig. 4) and did not react with any proteins found in the
noninfected cell lysate lane (lane 1 of Fig. 4).
PC4.9A6, PC4.9D3, PC4.7C2, and PC4.8D2 did not

Monoclonal antibodies
re~

:t consistently in this

assay giving spurious results that included high background in both the
infected and uninfected celllysates or not reacting at all.
In vitro and in vivo targeting of PCV-infected MHA hamster spleen
cells by FITC-labeled PC4.9A6 monoclonal antibody.

When FITC-labeled

PC4.9A6 was used to stain both PCV-infected and noninfected spleen cells in
vitro, there was only very weak reactivity with the cells as evidenced by
very low fluorescent intensity and cell numbers when the stained spleen
cells were analyzed by flow cytometry (data not shown). When the same
antibody was used to target the infected cells in vivo the FITC-labeled
PC4.9A6 reacted with the infected splenic macrophages. This is evidenced
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by a 400% increase in the overall fluorescent intensity and total fluorescent
cell numbers of in vivo stained splenic macrophages as opposed to the same
population of cells taken from in vivo stained, noninfected animals (Table
2, Figs. SA and SB, Figs. 6B, and 6C).

Background fluorescence of

nonstained, normal spleen macrophages is shown in Figure 6A.

DISCUSSION

The anti-PCV monoclonal antibodies PC4.9A6, PC4.9D3, PC4.8D2, and
PC4.7C2 were evaluated with regard to their isotype and subisotype,
reactivity with PCV-infected and noninfected acetone-fixed and living cells,
PCV peptide binding specificity, and their ability to target infected splenic
macrophages in the MHA hamster model of PCV-induced hemorrhagic
fever.

This study was undertaken to investigate the suitability of these

monoclonal antibodies as delivery vehicles for the targeted delivery of
antiviral compounds. These monoclonal antibody-drug conjugates could
possibly be used as therapeutic regimens for the treatment of human
arenaviral hemorrhagic fevers such as Lassa fever, Argentine hemorrhagic
fever, and Bolivian hemorrhagic fever for which there is still a substantial
mortality rate in regions where the viruses that cause these diseases are
endemic.
All four of the monoclonal antibodies were initially screened using
epifluorescence microscopy first against infected, acetone-fixed cells and
secondly, against living PCV-infected cells. All four demonstrated at least
some ability to bind to nonfixed, infected cells.

Monoclonal antibody

PC4.9A6 was selected as the candidate for further, more extensive,
evaluation on the basis of its ability to bind to nonfixed, living infected cells.
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Hoffman contrast microscopy, used in conjunction with epifluorescence
microscopy, revealed that PC4.9A6 was reacting with living PCV-infected
cells that appeared to be more rounded and refractile than similar cells that
had been fixed with acetone and then stained. It also showed that the
PC4.9A6 was reacting with a much smaller population of cells under
nonfixed conditions. Apparently, the intact, live, unfixed infected cells
were more resistant to staining with PC4.9A6.

The cells that were

specifically stained with PC4.9A6 may have had membranes that were more
porous or less resistant to penetration by the FITC-labeled conjugate.
Another explanation for this occurrence was that the infected cells, at some
point during the infection, had the PCV nucleoprotein on their surface as
shown by Zeller eta!. (19). Alternative routes of antigen presentation, such
as the exocytosis of protease degradation products from previously
endocytosed virus particles, may account for these observations (11) .
The monoclonal antibodies that were produced in our laboratories
immunoprecipitate two proteins from infected cell lysates, one of 64
kiloDaltons (kDa) and another of 38 kDa. Harnish et a!. (5) have reported
that proteins of these sizes correspond to PCV nucleoprotein (NP) and a
breakdown product of NP, respectively. It must be noted that Vezza eta!.
(15) have reported molecular masses of 66 kDa for NP, 64 kDa for GP1, and
38 kDa for GP2. The molecular masses of the proteins isolated with our
monoclonal antibodies tend to confirm the observations of Harnish et a!. (5)
with regard to molecular masses of the PCV proteins species .

The

monoclonal antibody 33.6 did not demonstrate any ability to bind GP2 using
the radioimmunoprecipitation technique.

The failure of the HHS and

monoclonal antibody 33.6 to precipitate any of the viral glycoproteins in this
assay may be due to the 12 h chase period used to radiolabel the infected
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cells. Because the glycoprotein precursor protein (GPC) is readily cleaved
into GPl and GP2, a lengthy chase period (>9 h) could result in the cleavage
and secretion into the medium of all radiolabeled viral glycoproteins. This
would result in the disappearance of the radiolabeled glycoproteins from
the infected cells lysates (5).
Immunodetection of viral and cellular proteins transferred to
nitrocellulose (Western blotting), using PC4.9A6, PC4.9D3, PC4.7C2, and
PC4.8D2 as the primary antibodies, did not yield satisfactory results due to
high background when these antibodies were used (data not shown). This
was in part due to the autonucleation of the silver intensifier used to
enhance the signal of the gold-conjugated secondary antibody used in the
immunodetection system. Another explanation for this lack of reactivity in
the Western blotting system was that the antibodies were reactive with a
conformational-dependent epitope that was destroyed or denatured during
the processing of the gels and the blots, although measures were taken to
minimize this problem.

Antibody 33.6 did react with a single 33 kDa

.;lycoprotein when it was used as the primary antibody for Western blotting.
Glycoprotein detection using concanavalin A and HRPO to localize cellular
and viral glycoproteins confirms that there is a major PCV glycoprotein
band at 33 kDa that most likely corresponds to GP2. The other viral
glycoprotein, GPl, migrated at 57 kDa. The PCV glycoprotein precursor
protein (GPC, -80 kDa) was not detected using this assay.

Further,

glycoprotein detection did not reveal a viral glycoprotein band at 64 kDa or
at 38 kDa. The presence of viral glycoproteins in these positions would
have been a strong indication that PC4.9A6, PC4.903, PC4.8D2, and PC4.7C2
did indeed react with viral glycoprotein antigens that may be more readily
accessible to antibodies on the surface of PCV-infected cells.
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Although PC4.9A6 apparently is not maximally bound to all live,
virally infected cells, the antibody does have some ability to target splenic
macrophages from PCV-infected hamsters when it was administered in
vivo.

Splenic macrophages from PCV-infected hamsters that were

inoculated with FITC-labeled PC4.9A6 on day 9 p.i. 8h prior to being
sacrificed demonstrated an average 400% increase in total fluorescence and
fluorescent intensity over similar uninfected animals when the samples
were analyzed using flow cytometry. Similar splenic macrophages, stained
in vitro and run in parellel, did not demonstrate this same targeting effect.
This suggests that the av;: ;Jability of free antigen may influence the uptake
of the FITC-conjugate.

It is possible that PCV may produce an over-

abundance of NP and that this may be accessible to the immune system.
Thus, the FITC-conjugate may be able to bind this free antigen and be
carried into the macrophages.

Another possibility is that the infected

macrophage may express portions of NP on its surface, perhaps in the
context of a class II histocompatability antigen, in its role as the antigenpresenting cell (APC) to thf immune system. Recent advances in the study
of antigen presentation by macrophages indicate that both antigens found
on the surface of virus particles as well as proteins from the interior of the
virion can be expressed on the surface of the APCs (9, 11, 16, 19). This may
allow for the conjugate to bind and be taken up into the cell even though
the conjugate is directed toward an internal viral protein. Lafon and Lafage
have demonstrated the antiviral activity of monoclonal antibodies directed
toward the internal proteins of rabies virus (9).

Also, Mills et a!. have

demonstrated that cytotoxic T cells were induced to proliferate when
exposed to APCs that expressed the internal matrix protein of influenza
virus (11). Thus, the monoclonal antibodies tested here may target infected

60
cells although they are directed toward an internal PCV protein. At least a
portion of the binding may be attributable to the presence of Fe receptors on
the surface of the macrophage. This appears the most likely explanation for
the binding of the FITC-labeled 9A6 to macrophages in noninfected
animals. The levels seen in this case more closely parallel the levels from
the in vitro targeting data. These lower levels may be attributable to low or
nonexistent levels of free antigen in the animals or in the cell culture
medium in which the in vitro targeting cells were stained.
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B

D

FIG. IV-1. Comparison of acetone-fixed PCV-infected and noninfected
Vero-76 cells stained with FITC-labeled PC4.9A6 using epifluorescence and
Hoffman contrast optics. A: Infected cells viewed with epifluorescence; B:
Noninfected cells viewed with epifluorescence; C: Same microscopic field
as A viewed with Hoffman optics; D: Same microscopic field as B viewed
with Hoffman optics (1200 x magnification).

62

A

D

c

FIG. IV-2. Comparison of live, unfixed PCV-infected and noninfected
Vero-76 cells stained with FITC-labeled PC4.9A6 using epifluorescence and
Hoffman contrast optics . A: Infected cells viewed with epifluorescence
(note stippled staining of infected cells); B: Noninfected cells viewed with
epifluorescence; C: Same microscopic field as A viewed with Hoffman
optics; D: Same microscopic field as B viewed with Hoffman optics. (1200 x
magnification).
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FIG. IV-3. lmmunoprecipitation of proteins from PCV-infected Vero76 cells radiolabeled with 35S-methionine by monoclonal antibodies
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FIG. IV-4. Western blot of PCV-infected and noninfected Vero-76 cells.
Lane 1:

noninfected Vero-76 cells probed with 33.6 as primary antibody.

Lane 2: PCV-infected Vero-76 cells probed with 33.6 as primary antibody.
Lane 3:

Glycoprotein detection of PCV-infected Vero-76 cells.

Glycoprotein detection of noninfected Vero-76 cells.

Lane 4:
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Fluorescent intensity

FIG.

IV-5.

Flow cytometry histograms of MHA hamster splenic

macrophages stained in vivo with FITC-labeled PC4.9A6. A: Noninfected
hamster spleen macrophages (n=5);
macrophages (n=4).

B:

PCV-infected hamster spleen
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FIG. IV-6.

Comparison of flow cytometry histograms of splenic

macrophages from MHA hamsters. A: Unstained, normal hamster spleen
macrophages; B: Noninfected hamster spleen macrophages stained with
FITC-labeled PC4.9A6;

C:

PCV-infected hamster spleen macrophages

stained with FITC-labeled PC4.9A6.
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Table IV-1. Reactivity of anti-PCV monoclonal antibodies in mouse
subisotype immunoassays.
Antibody
PC4.9A6

IgM

IgGl

IgG2a

PC4.9D3

+

PC4.7C2

+

PC4.8D2

+

NMsa
+
+
a NMS = normal mouse serum.

IgG2b

+

+

IgG3

IgA
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Table IV-2. Comparison of areas and mean channels from histograms A
and B of Figure 5.

Histogram

Percent of histogram to
the right of cursora

Mean
Channelb

A (Noninfected hamster)
8.33
36.3
B (PCV infected hamster)
41.81
41 .2
a Percentage of total area of the histogram found to the right of the cursor.
The cursor was set to exclude background fluorescence as determined by
the autofluorescence of nonstained MHA hamster splenic macrophages
as seen in Figure 6A.
b The mean channel of the FITC-9A6 fluorescence of the PCV-infected
hamsters is shifted 5.1 units to the right of the mean channel for the
normal control hamsters.
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CHAPTER V
CHARACTERIZATION OF THE RESPONSE OF MHA HAMSTERS TO
TREATMENT WITH ANTI-PICHINDE VIRUS MONOCLONAL
ANTIBODY-GELONIN IMMUNOCONJUGATE

An immunotoxin (IT) was produced by the conjugation of a phytotoxin,
gelonin, to a Pichinde virus (PCV) reactive monoclonal antibody, PC4.9A6.
This immunotoxin was tested in vivo in PCV-infected MHA hamsters, a
model for arenaviral hemorrhagic disease. The IT was not active against the
disease at the dosage tested and by the treatment route employed in this
study. The positive control, ribavirin, demonstrated a highly significant
(P <O.OOS) increase in survivors. Serum titrations indicated that 3 of the 5 IT

toxicity control animals had developed some humoral response that
inhibited the binding of PC4.9A6 to infected target cells. The hamsters did
not show any response to the gelonin moiety of the IT.

The targeting of anti-tumor drugs and phytotoxins to neoplastic and
virally-infected cells using immunologically reactive macromolecules is a
relatively new field of endeavor that has introduced a new degree of
specificity to the pharmacological action of these compounds. By chemically
linking the drugs or toxins to large protein molecules such as monoclonal
antibodies (1, 9, 11) or cellular virus receptors {5), a new dimension has been
added to the delivery of these compounds to specifically selected and targeted
cell populations. Fifty percent inhibitory dosages (IDsos) in the range of 10-11
M are not uncommon in determinations made using monoclonal antibodytoxin conjugates against cancer cells (8) whereas the 50% cytotoxic dosage
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(COso) in antigen-negative cells is on the order of 10-7 M resulting in a
therapeutic index (T. I. = COso/IDso) of 10,000.
In·a recent :Study, Ch:audhary·era.t.-(5) used the C04 antigen as a means of
targeting Pseudomonas exotoxin A to cells infected with the human
immunodeficiency virus (HIV), this resulted in specific killing of HIVinfected cells.

Human phase I trials using a mouse anti-human-COS

monoclonal antibody conjugated with ricin A chain have been undertaken
in patients with refractory chronic lymphocytic leukemia (9). This study
demonstrated that the treatment was well tolerated, although no beneficial
effect was observed in the patients.
In vitro and in vivo studies in other than human subjects cannot be
extrapolated directly to the human patient. In vitro and in vivo therapeutic
efficacy is not a guarantee that the therapy will work in humans as is
demonstrated in the human phase I leukemia study by Hertler et a!. (9)
referred to above. Even though the IT was binding to and saturating all of
the available binding sites on the lymphocytes of the patients, there was still
no therapeutic efficacy in preventing the recurrence of the leukemia. Thus,
surface binding is not the only criteria to be addressed in the development of
monoclonal antibody-directed delivery systems. The IT must also be readily
endocytosed, eventually releasing the toxin or drug into the cell (4). Antigen
density is another criteria that must be considered in the development of
vehicles for targeted delivery. Sufficient antigen must be readily accessible to
the IT. Low antigen density will prevent the uptake and subsequent release
of the toxin into the target cell. The simple fact that a molecule binds to the
surface of a cell does not ensure that this molecule is well suited as a targeted
delivery vehicle (8) .
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Prior studies indicated that FITC-labeled PC4.9A6 did target PCV-infected
cells in vivo. This is significant because it indicated that an immunoconjugate did reach the target population of cells. Thus, the in vivo efficacy of a
novel IT, PC4.9A6 conjugated with the ribosomal-inactivating protein
gelonin, against PCV-induced arenaviral hemorrhagic fever in MHA hamsters was evaluated in this study. Currently available therapeutic treatments
still have room for improvement in combating arenaviral hemorrhagic diseases in humans.

By targeting the gelonin to PCV-infected cells, it was

hoped that a therapeutic effect could be observed due to the selective elimination of PCV-infected

cell~

irom the still healthy cell population and the

concurrent reduction in the systemic toxicity of the toxin. Although this
therapeutic effect did not occur the experiment has helped to elucidate some
of the problems to be considered in using IT for antiviral therapy.

MATERIALS AND METHODS

Cells. The Vero-76 eel' - used in this study were obtained from the
American Type Culture Collection (Rockville, MD) . The cells were passaged
in minimum essential media (MEM, GIBCO, Grand Island, NY)
supplemented with 9% fetal bovine serum (FBS, Hyclone Labs, Logan, UT) .
For immunofluorescent assays in 96-well polystyrene plates (Corning,
Corning, NY), 0.1 ml of cells diluted to 4 x

ros cells/ml in MEM with 9% FBS

was added to each well.
Animals. The MHA hamsters used in this experiment were supplied by
Charles Ri ver Laboritories, Inc. (Wilmington, MA) .

The hamsters were

females that weighed approximately 40-50 g at the onset of the experiment.
The animals were quarantined for 24-48 h prior to use. The hamsters were
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housed five per cage in polycarbonate cages with corn cob bedding and were
provided with Wayne Lab Blox and tap water ad libitum.
Titration of PCV An4763 6-3-86 (B) virus pool in MHA hamsters.
Hamsters were infected subcutaneously (s.c.) with 0.2 ml of one-half logw
dilutions (l0-1.5 to 10·6) of PCV pool, PCV strain An 4763 of 6-3-86 (B) .
Animals were observed and counted on a daily basis. All days of death were
recorded. LDso and LD9o determinations were made using the method of
Reed and Muench (15).
Ribavirin and PC4.9A6-gelonin irnmunotoxin. 1-p-D-ribofuranosyl-1,2,4triazole-3-carboxamide (ribavirin) was provided by f ,e U. S. Army Medical
Research Institute for Infectious Diseases via Technassociates, Inc.
(Rockville, MD). The IT, PC4.9A6 conjugated with the A chain phytotoxin
gelonin (Sigma, St. Louis, MO), was prepared by Dr. Bill B. Barnett (Utah
State University, Logan, UT). The IT was shown to inhibit in vitro protein
sy nthesis when the disulfid e bridge connecting the gelonin to the
monoclonal antibody was chemically reduced. The immunotoxin was 16%
gelonin by weight (personal communication, B. B. Barn ·.:t).
In vivo determination of antiviral efficacy of the PC4.9A6-gelonin irnmunotoxin. Hamsters used for the determination of antiviral effectiveness
of the PC4.9A6-gelonin irnmunotoxin (IT) were all infected s.c. with 0.2 ml of
a PCV suspension containing one LD9o (80 immunofluorescent cell forming
units) of PCV strain An 4763. The infected hamsters were randomly divided
into six treatment groups of ten animals each. The treatment groups were as
follows : i)

PC4.9A6 treated (0.56 mg/kg / day); ii) Gelonin treated (0.1

mg / kg/ day); iii) PC4.9A6/ gelonin mixture (0.56 mg/kg/ day of PC4.9A6 + 0.1
mg/kg/ day of gelonin);

iv)

PC4.9A6-gelonin IT (0.66 mg/kg/ day); v)

Ribavirin (40 mg/kg/day); and vi) Saline. All treatments were performed
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once a day intraperitoneally (i.p.) on days 3-5 post-infection (p.i.) except for
the ribavirin-treated group that was treated twice a day on days 1-14 p.i. The
uninfected animals were housed completely separate from the infected
animals.

The toxicity control group consisted of five uninfected, PC4.9A6-

gelonin IT-treated hamsters.
untreated hamsters.

The normal controls were five uninfected,

Toxicity and normal controls were weighed

individually immediately prior to the first treatment and then again prior to
all subsequent IT treatments. After day 7 p.i., they were weighed on a weekly
basis. Toxicity controls were bled via the orbital sinus on days 3, 10, 17, 24,
and 31 p.i.
Production of hamster anti-gelonin serum. Four PCV-infected hamsters
that had been treated with gelonin and had survived the course of the
experiment were boosted with 0.1 ml i.p. of a 1 mg/ml dilution of gelonin in
sterile phosphate buffered saline (PBS), 8 weeks after the initial injections of
gelonin. Serum was collected from these animals and pooled 4 days after the
second injection of gelonin. Anti-gelonin activity of the hamster serum was
determined using an indirect enzyme-linked immunosorbent assay (ELISA)
as described below.
ELISA for the detection of the inhibitory effects of toxicity control
hamster sera on the binding of PC4.9A6 to PCV-infected Vero-76 cells.
Twenty-four hour confluent monolayers of Vero-76 cells in microtiter plates
were infected with PCV were fixed as previously described (3), and stored at
-20°C until used.

The cells were infected with a dilution of PCV that

maximized the observable fluorescence of the acetone-fixed infected
monolayers when stained with a PC4.9A6-FITC conjugate .

Ten-fold

dilutions (10-1 to 10-4) of serum collected from the IT toxicity control animals
were made in dilution buffer (PBS with 0.1% BSA (Jannsen, Piscataway, NJ]
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and 0.1% sodium azide [Kodak, Rochester, NY]). To each dilution of hamster
serum (0.9 ml) was added 0.1 ml of a 60
antibody (final concentration ·6

~g/ml) ;

~g/ml

dilution of purified PC4.9A6

The dilution tubes were incubated in

a waterbath at 37°C for 1 h. Triplicates of the dilutions were plated (25
~!/well)

on the fixed, infected microtiter plates. Normal hamster serum,

PC4.9A6 alone (6
~g/ml

~g/ml),

rabbit anti-PC4.9A6 serum (1 :100 dilution) with 6

PC4.9A6, pooled IT toxicity serum without PC4.9A6, and nontreated

blanks were included as controls. The plates were wrapped in Saran Wrap®
and incubated for 1 h at 37°C. After incubation, the plates were washed three
times with dilution buffer and 50

~I

of a 1:1000 dilution of goat anti-mouse

IgG-urease conjugate (Sigma, St. Louis, MO) was added to each well. Urease
is an enzyme isolated from Canavalia ensiformis (Jack bean) that is not
found in mammalian cells. Urease catalyzes the cleavage of ammonia from
urea causing an increase in the pH of weakly buffered solutions.

This

increase in pH is detected, either visually or spectrophotometrically, as a
change in the color from yellow to purple of the pH indicator bromcresol
purple in the urease chromogen (13) . The plates were incubated for 2 h at
37°C, after which the urease conjugate was decanted from the plates and the
plates were washed three times with water. Urease chromogen (80 mg/1
bromcresol purple, 0.15 mM NaOH, 0.1% urea, and 0.2 mM EDTA, pH 4.6,
100

~!/well)

was added to the plates, and the plates were incubated until the

positive controls reached an endpoint. Absorbance at 590 nm was read on a
BioTek microplate reader.
ELISA for the detection of anti-gelonin antibodies in hamster sera.
Round bottom ELISA plates (Immulon 2, Dynatech Labs, Inc., Chantilly, VA)
were coated with gelonin (10

~g/ml)

by adding 0.1 ml/well of gelonin

diluted in coating buffer (0.1 M carbonate, ph 9.6). The plates were incubated
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for 24 h at 4°C, after which they were washed four times with water and
allowed to dry. Coated plates were stored at -20°C until used.
Remaining protein binding sites on the gelonin-coated plates were
blocked prior to use by adding 100 Ill of blocking buffer (5% BSA in PBS) to
each well and incubating at 4°C overnight. Dilutions (l0-1 to 10-4) of hamster
sera in dilution buffer were made. To each well of the microtiter plate was
added 25 Ill of the appropriate dilution of hamster sera and the plates were
allowed to incubate for 1 hat 37°C. The plates were washed three times with
dilution buffer. Fifty Ill/well of the urease conjugate (Sigma) diluted 1:1000
in '.1.ilution buffer was added to the plates and they were further incubated at
37°C for 2 h. The plates were then washed three times with water and 100
Ill/well of urease chromogen was added.

Wells treated with normal

hamster serum and hamster anti-gelonin serum, as well as nontreated wells,
were included as controls.

Plates were incubated until positive control wells

reached an endpoint. Absorbance at 590 nm was then read on a BioTek
microplate reader.
r ~atistical

evaluation. Increases in survivors were evaluated using Chi-

square analysis with Yates' correction. Mean survival time of the treated
hamsters was evaluated using Student's t-test. Data from the mouse antiPC4.9A6 assays and from the mouse anti-gelonin assays were analyzed by
analysis of variance using a randomized block design.

RESULTS

Titration of PCV in MHA hamsters. Hamsters infected with PCV had an
average day of death of 10.7 ± 2.1 days (Fig. 1). The LDso titer of this virus
pool was 1.6 x 106 LDso/ml.
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Effects of i.p. treatment with PC4.9A6-gelonin IT. The data from the
experiment performed to investigate the antiviral efficacy of the IT is
summarized in Table 1. There was no significant increase in survivors or in
mean survival time in any of the treatment groups, except for the ribavirin
group (10) that showed a highly significant (P<0.005) increase in survivors.
Increase in mean survival time for the ribavirin-treated group would have
been statistically significant except for one death that occurred on day 20 p .i.
(Fig. 2). Days of death data are shown in Figure 3.
Toxicity of PC4.9A6-gelonin IT. Data from the toxicity controls collected
during the first week of treatrne ·"lt suggests that there may have been some
host toxicity associated with the administration of the IT, as indicated by the
decrease in the average weights of the IT-treated animals after day 3 p.i (Fig.
4). The toxicity controls were able to overcome this initial toxicity and went
on to gain normal or above amounts of weight after day 4 p.i. (Fig. 5).
Normal controls did not manifest any loss of weight throughout the course
of this experiment.
Humoral response of MHA h: msters to IT treatment.

Analysis of the

data collected from ELISA for the inhibition of PC4.9A6 binding to PCVinfected Vero-76 cell by dilutions of serum collected weekly from the IT
toxicity control animals revealed that there was a highly significant (P<O.OOl)
inhibition (Table 2, Figs. 6 and 7). At the 10-1 dilution of hamster serum
taken at week 1 (Fig. 6), there is a significant decrease in absorption,
indicating that there is a component in this dilution of serum that prevents
the binding of PC4.9A6 to infected cells. When the same data was plotted
with respect to the time of sample collection and holding the dilution
constant (l0-1 dilution, Fig. 7), the data indicate that there were 3 of the 5
animals whose serum appeared to at least partially block PC4.9A6 binding.
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The data from the 10-2 dilution of hamster serum, plotted in the same
fashion, demonstrated that this effect was no longer present at this dilution
(Fig. 8). The same was true for the lQ-3 and J0-4 dilutions in this assay (data
not shown).

Positive control serum, rabbit anti-PC4.9A6, was able to

completely inhibit antibody binding in this assay (Fig. 6).
The same dilutions (l0-1 to J0-4) of hamster serum were tested for their
gelonin binding activity employing an indirect ELISA.

There was no

significant reaction of the toxicity control hamsters to the gelonin moiety of
the IT as evidenced by the lack of reactivity in these assays (Table 2). Positive
control serum (hamster anti-gelonin) did react in this assay rF1g. 9) . Normal
hamster serum used as a negative control in this assay demonstrated more
reactivity with gelonin than the IT toxicity control animals serum at a 10-1
dilution, although it did not surpass the positive control serum in its
reactivity with gelonin (Figs. 9 and 10).

The apparent reactivity of the

normal hamster serum was abolished at the 10-2 dilution (Fig. 11). It should
also be noted that pre-treatment serums, collected from the IT toxicity
control animals prior to IT treatment, did not demonstrate inc-eased gelonin
reactivity at the 10-1 dilution (Figs. 9 and 10).
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DISCUSSION

Several recent studies using monoclonal antibodies conjugated to A
chain toxins, including gelonin, have suggested that these immunotoxins
are able to specifically kill either lymphoid or tumor cells in vitro and in
vivo (12, 14). A similar approach using Pseudomonas exotoxin A conjugated
to recombinant human CD4 has been shown to selectively kill HIV-infected
cells in vitro (5).
Because of the success in using these immunotoxins against cancer and
HIV infection, an application of this approach was sought for the inhibition
of PCV-infected cells. Gelonin appears to be particularly attractive for this
application because it is not toxic to intact cells and must be transported into
the cell in order for it to inhibit protein synthesis via the enzymatic
inactivation of ribosomes (6, 16). The IT used in this study is approximately
16% gelonin by weight and has been shown to inhibit in vitro protein
synthesis when the disulfide bonds linking the gelonin to the antibody are
chemically reduced (B. B. Barnett, Utah State University, Logan, UT,
personal communication) .
The data from this experiment indicate that the IT is not having the
desired effect in preventing hemorrhagic disease in this model (Table 1).
The positive control, ribavirin (10), confirmed that the hemorrhagic disease
model could be successfully treated by conventional antiviral chemotherapy.
The PC4.9A6 only, gelonin only, PC4.9A6 + gelonin, and saline treated
controls also did not have a significant effect on extending the survival time
or number of survivors in the infected hamsters.

The lack of IT activity in

this model could be due to a number of factors such as insufficient dosage of
IT, the blocking of the antigen binding site of the antibody by free viral
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antigen in the blood and serum, the timing of the adminstration of the IT,
or that the IT is not taken up by the infected cells. The dosage of IT used in
this experiment is similar to the dosages that have shown tumor and HIVinfected cell killing activity in other systems (5, 7) . In addition, the host
weight loss occurring in the toxicity control animals treated with IT suggests
the maximum tolerated dose was approached in this experiment.
Serum from 3 of the 5 IT toxicity control hamsters demonstrated
significant ability to inhibit the binding of PC4.9A6 during the first week after
the animals were treated with IT. The apparent reaction of these hamsters to
the antigen-binding portion of PC4.9A6 of the IT was indicative th? ~ there
may have been an antiidiotypic response induced due to treatment with the
IT.

The humoral response of these hamsters was weaker than the anti-

PC4.9A6 serum that was used as a positive control, although still highly
significant, but these animals were treated with what would be considered a
very poor immunization schedule, if induction of anti-PC4.9A6 antibody
was to be the end of the experiment. Because the hamster and the mouse
appear to be genetically closely related, an antiidiotypic response by a hai .•ster
to the immunoglobulin is an interesting effect. It should be noted that the
appearance of the PC4.9A6-inhibitory substance in the serum of the toxicity
control hamsters does not appear to develop as a classical immune response
to a foreign antigen, that is with a well defined lag period that gradually
increased over time to a maximum titer.

The inhibition was noted

immediately after treatment with the IT and dropped off within a week of
the cessation of treatment. The total anti-PC4.9A6 response of the IT toxicity
control hamsters was not done because of the innate cross reactivity of antimouse reagents with hamster antibodies.

This genetic relatedness of the

mouse and the hamster may be what was responsible for the development of
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the "antiidiotypic" response of the hamster to the mouse immunoglobulin.
It is conceivable that the only region of the immunoglobulin to which the

hamster could react was the hypervariable region of the mouse
immunoglobulin and that this response was what blocked that binding of
PC4.9A6 to PCV-infected cells in the ELISA.
In general, the phytotoxins such as ricin, abrin, and gelonin are
considered to be immunogenic in animals (1) .

The lack of a humoral

immune response by the hamsters to the gelonin indicates that there must
have been only very low amounts of gelonin on the antibody molecule.
Since the IT was 16% gek'lin by weight, this indicates that there was
probably only one or two molecules of the toxin on the antibody molecule.
This may not have been enough to induce an adequate immune response to
the phytotoxin, though it would have been sufficient to induce the catalytic
inactivation of the 28 S ribosomal subunits of the cells if the toxin had
penetrated to the interior of the infected cells.
In conclusion, there are several possible explanations for the lack of
reactivity of the monoclonal ar.:ibody toxin conjugate that was tested in this
PCV-MHA hamster model of arenavirus-induced hemorrhagic disease. The
immunotoxin was probably reaching at least some of the infected target cells
in the animals. This was demonstrated in an earlier report (Chapter 4). The
lack of reactivity in this system could be due to lack of expression of PCV
nucleoprotein (NP) on the surface of the infected cells to which this antibody
could bind to early in the infection process. It is possible that low levels of
this antigen in the serum or other serum components such as antiidiotypic
antibody directed against the paratope of PC4.9A6, would not allow this
antibody to bind readily to the infected cells. There may not have been
enough virus replication and infection of the target cells by days 3, 4, and 5
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p .i. for IT to be targeted. If this is the case, another antibody, directed against
an antigen expressed earlier on the surface of infected cells, should be
selected as the target antigen.
Another possibility is that killing the infected cells is not sufficient to
stop the virus infection or that virus replication in some other way eclipses
the activity .of the IT. If antigen availability is required prior to the targeting
of the IT to infected cells, then there may already be enough virus assembled
in the infected cells to go on and infect another round of cells after the cell is
inactivated by the IT. This condition may be further aggravated if the
immunotoxin was taken up into the cell and the toxin p0rtion was
hydrolyzed from the IT, even though this was a desirable occurrence in order
for the inactivation of ribosomes to occur.

The hydrolyzed toxin would

then have lost its ability to penetrate any more infected cells, due to the
nature of the A chain toxin, and would be subjected to immediate clearance
from the animal (2).
This experiment pointed out the large number of variables that require
consideration in attempting to target toxins using monoclonal a- tibodies.
Surface reactivity or reactivity with live cells should not be the only
considerations given to screening antibodies for their potential as toxin
delivery vehicles. By incoporating a step in the initial monoclonal antibody
screening procedures that allows for the evaluation of many candidate
monoclonals, perhaps a more critical evaluation of the specific monoclonals
can be made. This step could take the form of an indirect assay using goat
anti-mouse, or another such antibody, conjugated with the toxin of interest
to evaluate the targeting potential of all candidate monoclonal antibodies.
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Figure V-5. Weekly average weights of IT toxicity and normal MHA
hamster controls. Toxicity controls did not demonstrate any cumulative
toxic effects over the course of the experiment.
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Figure V-6. ELISA of the inhibitory effects of IT toxicity control hamster
sera on PC4.9A6. Sera from 3 of 5 hamsters demonstrated significant inhibitory
effects on PC4.9A6 binding to PCV-infected cells at week 1 at a 1:10 dilution.
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Figure V-7. ELISA of the effects of IT t0xicity control hamster
sera on PC4.9A6 (1:10 dilution). Effect of IT toxicity control hamster
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inhibition of PC4.9A6 binding to PCV-infected cells, absorbance
plotted with respect to time.
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Table V-1. Effect of i.p. administrationa of PC4.9A6-gelonin IT on PCVinfection in 3-4 week old MHA hamsters.

Treatmenta

Start of
Dose
No. Survivors/ Mean survival
Treatmentb (mg/kg/day)
Total
timec (days)

PC4.9A6 only
72 h
72 h
Gelonin
PC4.9A6/Gelonind 72 h
PC4.9A6-Gelonin JTe 72 h
Ribavirinf
24 h
72 h
Saline

post
post
post
post
post
post

0.56
0.10
0.56/0.10
0.66
40.0
0

0/10
4/10
1/10
0/10
9/10g
4/20

10.5
13.0
13.8
10.7
20.0
12.3

Toxicity controls: The IT toxicity controls all survived at a similar dose level
and all lost weight after the first day of treatment, although they did begin to
gain weight after the third day of treatment. Normal controls did not exhibit
this loss of weight (Fig. 2).
a Treatment once daily on days 3, 4, and 5 p .i. unless otherwise noted.
b Relative to virus inoculation.
c Animals dying on or before day 21.
d A noncovalently linked mixture of the antibody PC4.9A6 and gelonin.
e A covalently linked conjugate of PC4.9A6 and gelonin.
f Treatment twice daily beginning 24 h p.i. on day 1 to day 14.
g P<0.005.
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Table V-2. Analysis of variance of the anti-PC4.9A6 and the anti-gelonin
activity of serum collected from toxicity control MHA hamsters for
experimental weeks 0, 1, and 2.
Source of
variance

Main Effects
Hamster (H)
Dilution (D)
Error (Hx D)
Time (T)
Error (H x T)
Interactions
Dilution x
Time
Error (H x [D x T])
Total

Dpa

Anti-gelonin activity
F value
P value

4
3
12

112.3

<0.001

30.35

<0.001

2

9.624

<0.01

5.435

<0.05

8.702

<0.001

<1

N . S.b

8

6
24
59

a Degrees of freedom.
b Not significant.

Anti-PC4.9A6 activity
P value
F value
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CHAPTER VI
SUMMARY AND FUTURE DIRECTIONS
Although treatment of Pichinde virus (PCV)-infected hamsters with
immunotoxin (IT) did not prevent the development of disease, this model
of directed delivery does demonstrate the potential for the in vivo targeting
of PCV-infected cells. As is shown in chapter IV, the flourescein-PC4.9A6
conjugate (FITC-9A6) demonstrated the ability to specifically bind to PCVinfected cells. This is an indication that the system was effective in targeting
immunoconjugates and that the process of conjugation did not destroy the
ability of the monoclonal antibody to bind to infected cells. The lack of
antiviral activity of the IT treatment used in this study could be due to a
number of different reasons such as insufficient toxin on the conjugate to
effectively kill the cell, though one molecule of toxin should have been
adequate if it was taken into the cell. Another possibility is that the toxin
was cleaved from the monoclonal antibody and eliminated from the animal
prior to the antibody reaching the target cell. Also, the surface binding of
monoclonal antibodies to infected cells may not be sufficient to ensure
delivery of the toxin to the interior of the cell. It should be noted that viral
antigen on the surface of a cell is considered to be on its way out of the cell as

it is incorporated into a viral particle and not returning to the interior of the
cell. Thus, there are a number of possible reasons that this particular IT
treatment regimen was not effective.

The optimization of several

parameters, such as the viral target antigen, the appropriate toxin, the most
efficient means of covalently linking the toxin to the antibody, as well as the
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trreatment route and schedule, needs to be undertaken before this approach
to the antiviral immunoconjugate therapy can be utilized successfully.
Initially, there is a need to demonstrate, in vitro, if possible, that virus
replication and spread to other noninfected cells can be prevented by using a
targeted toxin delivery system based on either polyclonal or monoclonal
amtibodies. This could take the form of an indirect screening procedure in
wrhich polyclonal sera or an extensive panel of monoclonal antibodies,
d cirected against a number of viral antigens and immunologically distinct
ejpitopes, are used as the primary antibody.

This could also include the

testing of several different isotypes and subisotypes of antibodies, perhaps
th1at are directed against the same epitope, in order to determine the effect of
is•otype and subisotype on antibody uptake into infected cells. The secondary
amtibody should be directed against the immunoglobulin from the species
fnom which the polyclonal sera or monoclonal antibodies were derived. The
secondary antibody could then be conjugated with any of a number of
plhytotoxins or bacterial toxins such as gelonin, ricin A chain, abrin,
d iiphtheria toxin, or Pseudomonas exotoxin A to name a few. Inhibition of
either viral CPE or fluorescence due to viral antigen would be indicative of a
successful combination of primary and secondary antibodies. An in vitro
screening system for antiviral activity appears to be the only practical and
ce>st effective alternative for screening the large numbers of potential
primary and secondary antibody combinations, although it may not be as
ef-fective in ensuring the delivery of the biologically active macromolecules
to the target cells.
In vitro targeting could also be investigated as a possible screening
method using fluorescent microscopy. By employing secondary antibodies
fluorescently tagged with a green molecule, the surface binding of the

•
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primary antibody could be investigated in live cells. The Fe binding of the
live cells could be blocked by using an unlabeled, irrelevant antibody derived
from a species other than that from which the primary antibody was
prepared. This would allow for the detection of virus-specific reactivity of
the primary antibody on the surface of infected cells.

In a parallel

experiment, the secondary antibody that has been conjugated with the toxin
molecule could be added to the cells. Following this step, a third or tertiary
antibody, directed against the toxin moiety of the IT, bearing a red fluorescent
label could be added . This would allow for the detection of toxin on the
surface of infected cells when probed with the secondary antibody. This
could be performed on cells that had been fixed or on live cells in order to
demonstrated binding and uptake. Similar experiment could be performed
using radiolabeled primary, secondary, and tertiary antibody preparations.
Also, in vivo experiments could be done similar to those performed in
chapter V, once the basic parameters had been optimized in vitro.
Once this system has been optimized, it would be an excellent system for
the screening of antiviral drug-monoclonal antibody conjugates in order to
evaluate the efficacy of these compounds in combating viral disease.

An

approach similar to that described for immunotoxin evaluation could be
taken in developing indirect screening procedures for the evaluation of
antiviral drug-monoclonal antibody conjugate therapy.
In conclusion, the development of monoclonal antibody-directed drug
or toxin delivery systems is not simply a

~atter

of producing antibodies and

then using them for targeting infected cells. Surface binding of monoclonal
antibodies to infected cells, though it is an important criterion, does not
appear to be the sole criterion for the selection of an antibody for use in this
targeted delivery system. The selection of antibodies that target and deliver
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toxins or drugs to infected cells does appear to be an extremely complex
process that requires the optimization of many parameters before optimal
results can be observed. The questions with regard to which antibodies are
best suited for use in this system may best be answered by developing an
indirect procedure for the screening of large numbers of potential antibodies.
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